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Depuis	 le	 début	 de	 ma	 thèse	 de	 doctorat,	 mon	 entraînement	 était	 concentré	 sur	 la	



























































































in	dense	connective	 tissue	 forming	a	supportive	wall	of	 the	eyeball.	 It	 is	continuous	with	
the	cornea,	a	transparent	tissue	that,	together	with	the	lens	make	the	optical	system	of	the	
eye,	providing	a	sharp	image	at	the	 level	of	the	retina.	The	second,	or	 intermediate	 layer,	
consists	in	an	anterior	part,	with	the	iris	and	the	ciliary	body,	which	regulate	the	amount	of	
light	 getting	 into	 the	 eye,	 and	 a	 posterior	 part,	 the	 choroid,	 consisting	 in	 a	 highly	
vascularized	membrane	nourishing	the	particularly-demanding	cells	of	the	retina.	Finally,	
there	is	the	retina,	that	makes	the	third	and	most	internal	layer,	consisting	in	the	sensory	
part	 of	 the	 eye.	 All	 ocular	 structures	 are	 important	 for	 proper	 vision,	 but	 the	 retina	 is	
probably	the	most	essential	because	it	harbors	photoreceptors,	where	light	is	captured	and	












and	 is	 responsible	 for	 giving	 us	 sharp	 central	 vision	 and	 fine	 details,	with	 the	 very	 best	
vision	provided	by	the	tiny	depression	at	its	center,	namely	the	fovea.	The	optic	disk,	also	
called	“blind	spot”	because	of	its	lack	of	photoreceptors,	is	where	all	axons	of	the	ganglion	
cells	 meet	 to	 form	 the	 optic	 nerve.	 Millions	 of	 photoreceptors	 are	 capturing	 the	 light,	
generating	 action	 potentials	 that	 travel	 throughout	 the	 optic	 nerve,	 towards	 the	 brain’s	
visual	 centers.	 Before	 reaching	 the	 photoreceptor	 layer,	 light	must	 go	 through	more	 cell	
















function	 in	 the	 transmission	 of	 the	 signal	 from	 the	 photoreceptor	 to	 ganglion	 cells,	
amacrine	cells	are	interneuronal	cells,	and	function	more	as	“message	collectors”.	Bringing	








light	 signal	 transmission	 to	 the	 brain.	 Generally,	 in	 the	 vertebrate	 retina	 there	 are	 two	
types	of	photoreceptors:	rods	 and	cones.	Despite	 their	 fundamentally	 similar	 structures,	
they	 accomplish	 distinct	 functions,	with	 responses	 to	 different	 light	 intensities	 and	with	
varying	 densities	 along	 the	 retina.	 Rods	 are	 very	 numerous	 (110-125	millions)	 and	 are	
specialized	 in	vision	at	 low	 light	 levels9.	They	are	mainly	present	 in	 the	periphery	of	 the	
retina,	 and	 their	 density	 decreases	 towards	more	 central	 areas,	 reaching	 absence	 in	 the	
foveal	 region.	 On	 the	 other	 hand,	 cones	 (6.4	millions)	 provide	 sharp	 and	 color	 vision	 in	
daytime	 lighting	 conditions	 and	 are	 primarily	 located	 in	 the	 fovea	 and	 its	 surrounding	
area9.	
This	cone-	or	rod-specific	light	absorption	is	mediated	by	the	presence	of	distinct	opsin	
molecules	 that	 are	 capable	 of	 absorbing	 different	 wavelengths.	 Rhodopsin,	 making	 the	
photopigment	 of	 rods,	 has	 indeed	 a	 great	 sensitivity	 and	 it	 is	 able	 to	 detect	 very	 low	
amounts	 of	 light.	 Conversely,	 cones	 are	 constituted	 of	 less	 sensitive	 opsins,	 but	 they	 are	
much	more	discriminating	 for	 specific	wavelengths.	 In	human,	 three	different	 opsins	 are	




with	 several	 membrane	 discs	 (the	 outer	 segment).	 This	 atypical	 structure	 increases	 the	
surface	area	for	light	capturing.	The	photopigment-containing	outer	segment	is	connected	
to	the	inner	segment	through	a	narrow	section,	the	so-called	connecting	cilium	(Figure	3).	
All	 proteins	 destined	 for	mantainance	 of	 the	 outer	 segment	must	 pass	 through	 this	 thin	
portion	of	the	photoreceptor.	The	photoreceptor	inner	segment	contains	the	endoplasmic	
reticulum,	the	Golgi	apparatus,	and	mitochondria	densely	packed	near	the	outer	segment,	








Phototransduction	 is	 the	 process	 of	 conversion	 of	 light	 into	 biological	 signals.	 This	
occurs	 thank	to	the	photopigments	present	 in	 the	outer	segment	of	photoreceptors.	Each	
photoreceptor	 type	 has	 specialized	 photopigments,	 consisting	 in	 a	 protein	 moiety,	
belonging	 to	 the	 class	 of	 opsins,	 conjugated	 to	 a	 small	 light-absorbing	 compound,	 called	
chromophore,	and	derived	from	vitamin	A	(also	known	as	retinal).	Throughout	the	animal	
kingdom	 there	 is	 variation	 in	 the	 structure	 of	 photoreceptors,	 nonetheless	 the	
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phototransduction	 cascade	 is	 highly	 conserved	 and	 is	 based	 almost	 exclusively	 on	 the	
function	of	opsins13.		
When	light	reaches	the	photoreceptor,	the	chromophore	isomerizes	from	11-cis-	to	all-
trans-retinal,	 leading	 to	 a	 conformational	 change	 of	 the	 opsin.	 As	 a	 consequence	 of	 this	
chemical	shift,	a	specific	G-protein	called	transducin	is	activated.	The	cascade	follows	with	
transducin	 activating	 a	 phosphodiesterase,	 which	 is	 responsible	 for	 the	 breakdown	 of	
cGMP,	 leading	to	closure	of	cGMP-gated	cation	channels	and	causing	hyperpolarization	of	
the	membrane	with	the	consequent	decrease	in	release	of	the	neurotransmitter	glutamate.	










called	 visual	 cycle.	 All-trans	 retinal	 is	 transported	 to	 the	 RPE	 for	 recycling	 and	 is	 then	










it	 is	 suggested	 by	 its	 name	 its	 function	 is	 to	 anchor	 the	 cilium	 to	 the	 endoplasmatic	
reticulum18.	The	CC	is	the	backbone	of	the	axoneme	and	corresponds	to	the	transition	zone	
between	 outer	 and	 inner	 segments.	 Connecting	 axoneme	 and	 BB,	 it	 works	 as	 a	 bridge	
between	these	two	structures.	As	depicted	in	Figure	5,	there	is	a	high	flow	of	proteins	from	
the	inner	to	the	outer	segments.	This	flow	is	mediated	through	the	intraflagellar	transport	


















The	 building	 blocks	 of	 microtubules	 are	 α-	 and	 β-monomers	 of	 tubulin,	 configured	 into	
helical	 patterns	 of	 protofilaments.	 In	 motile	 cilia,	 microtubules	 are	 disposed	 in	 the	
canonical	 9+2	 pattern,	 and	 are	 studded	 with	 dynein	 arms	 that	 contain	 adenosine	
triphosphatases	 (ATPases).	 These	 act	 as	 molecular	 motors	 allowing	 the	 sliding	 of	 the	
peripheral	microtubular	pairs	and	producing	movement20.	On	the	other	hand,	primary	cilia	
have	 a	 9+0	 conformation.	 In	 the	 case	 of	 embryonic	 nodal	 cilia,	 dynein	 arms	 are	 also	
present,	 and	 direct	 a	 certain	 type	 of	 movement	 that	 is	 required	 for	 correct	 organ	
positioning	 during	 embryologic	 development	 as	well	 as	 for	 detection	 of	mechanical	 and	




Inherited	 retinal	 disorders	 (IRD)	 are	 a	 class	 of	 genetic	 diseases	 leading	 to	 the	
progressive	loss	of	vision	as	a	consequence	of	photoreceptor	degeneration.	IRDs	present	an	
astonishing	amount	of	heterogeneity	both	at	the	genetic	and	phenotypic	levels.	In	fact,	this	
heterogeneity	 is	displayed	not	only	by	mutations	 in	different	genes	associated	 to	a	 same	
phenotype,	but	also	by	diverse	phenotypes	caused	by	different	mutations	in	the	same	gene	
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(Figure	 7).	 IRDs	 are	 usually	 rare	 and	monogenic	with	 a	 prevalence	 in	 the	 population	 of	
about	 1	 in	 3,000	 individuals19.	 To	 date,	 a	 number	 of	 genes	 have	 been	 associated	 with	













The	 most	 prevalent	 IRD	 is	 retinitis	 pigmentosa	 (RP),	 affecting	 approximately	 1/4000	
individuals	 worldwide6,25,26.	 It	 is	 primarily	 characterized	 by	 a	 poor	 night	 vision,	 due	 to	
degeneration	of	rod	photoreceptors.	The	age	of	onset	of	RP	is	variable,	developing	in	most	
of	 the	cases	during	mid-adulthood.	Due	to	 its	variable	phenotype,	 the	diagnosis	 is	mainly	
done	by	electrophysiology	(electroretinogram	(ERG))	and	imaging	analysis	(ophalmoscopy	
or	 slit	 lamp	 fundoscopy,	 and	 optical	 coherence	 tomography	 (OCT)).	 Typically,	 fundus	
imaging	 of	 RP	 patients	 reveals	 pigmented	 deposits	 in	 the	 periphery	 of	 the	 retina	 (also	
called	 bone	 spicule	 deposits).	 This	 pigmentation	 is	 due	 to	 the	 migration	 of	 the	 retinal	
pigment	 epithelium	 into	 the	 neural	 portion	 of	 the	 retina,	 as	 a	 consequence	 of	
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photoreceptor	 cell	 death27.	With	progression	of	 the	disease,	 cones	 and	 central	 vision	 are	
also	affected,	with	cases	that	result	in	complete	blindness.	On	the	contrary,	cone	(CD)	and	
cone-rod	 degenerations	 (CRD)	 consist	 in	 the	 primary	 loss	 of	 cones,	 followed	 by	 the	
progressive	degeneration	of	rods	and	the	peripheral	retina	in	CRD.	The	disease	progression	
is	 generally	 more	 severe	 than	 in	 RP.	 In	 CD	 and	 CRD,	 the	 first	 signs	 of	 the	 disease	 are	
disturbance	of	the	central	and	colour	vision,	with	retinal	pigment	deposits	appearing	in	the	
macula.	 Subtypes	of	CD	depend	on	 the	 loss	of	 specific	 cone	photoreceptors	and	 they	 can	
result	 in	 achromatopsia.	 The	 most	 severe	 form	 of	 IRD	 is	 considered	 to	 be	 Leber	
congenital	amaurosis	(LCA),	with	severe	 loss	of	photoreceptors	 in	the	 first	years	of	 life.	
LCA	often	comprises	other	ocular	features,	such	as	nystagmus	and	amaurotic	pupils.	With	a	
prevalence	 of	 1	 affected	 individual	 every	 30,000	 newborns,	 it	 is	 considered	much	 rarer	
than	RP.28	









of	 BBS	 patients	 include	 retinal	 degeneration,	 obesity,	 polydactyly,	 renal	 and	 genital	
abnormalities,	 as	well	 as	 intellectual	disabilities.	However,	 the	disease	 can	manifest	with	
high	 variability,	 even	within	 affected	 family	members,	 and	 sometimes	 include	 additional	
phenotypes.	 This	 syndrome	 is	 very	 rare,	 and	 affects	 1	 person	 in	 120,000	 individuals	 of	




in	 the	eyes	and	 in	renal	 function.	Specifically,	patients	show	nephronophthisis	 (a	 form	of	
cystic	kidney	disease)	and	RP	(or	in	some	cases	a	diagnosis	of	LCA	because	of	more	severe	
phenotype).	 Genes	 causatives	 for	 Senior	 Løken	 have	 been	 found	 to	 participate	 in	 the	
structure	and	function	of	primary	and	motile	cilia.	An	example	of	these	is	the	NPHP1	gene,	
mutated	 in	 approximately	 20%	 of	 all	 cases.	 NPHP1	 (Neprhocystin1)	 has	 been	 shown	 to	
	14	
localize	 to	 the	 transition	 zone	 of	 the	 renal,	 respiratory	 and	 photoreceptor	 connecting	
cilia33.	In	vivo	and	in	vitro	studies	have	demonstrated	that	NPHP1	interacts	and	co-localize	
with	 different	 other	 ciliary	 proteins	 that	 are	 known	 to	 cause	 Senior	 Løken	 syndrome,	
including	nephrocystin-3,	-4	and	inversin34–36.	However,	individuals	with	defective	NPHP1	
have	 also	 been	 described	 suffering	 from	 Bardet-Biedl	 syndrome	 and	 another	 syndromic	
entity,	 Joubert	 syndrome,	demonstration	 that	 the	NPHP1-related	disease	 is	 characterized	
by	phenotypic	heterogeneity.	
The	 Joubert	 syndrome	 (1	 affected	 in	 100,000)	 is	 characterized	 by	 hypoplasia	 of	 the	
cerebellar	 vermis	 and	 accompanying	 neurologic	 symptoms,	 including	 dysregulation	 of	





consisting	 in	 ciliary	 dysfunction.	 This	 class	 of	 diseases	 is	 more	 frequently	 called	
“ciliopathy”.	Ciliopathies	 involve	 deficiencies	 in	 ciliary	 and	 cilia-associated	 proteins	 and	




Cilia	 and	 flagella,	 highly	 conserved	 in	 their	 core	 structure,	 are	 ancestral	 organelles	
composed	of	more	than	650	proteins41.	Cilia	play	crucial	roles	in	normal	function	of	most	
tissues	 of	 the	 human	 body,	 including	 development,	 tissue	 morphogenesis	 and	
homeostasis40.	 Some	 examples	 of	 diseases	 affecting	 primary	 cilia	 are	 polycistic	 kidney	
disease,	 Usher	 syndrome,	 retinitis	 pigmentosa,	 Bardet-Biedl	 syndrome	 and	 Joubert	
syndrome.	 On	 the	 other	 hand,	 motile	 cilia	 defects	 have	 been	 shown	 to	 be	 causative	 for	









Next	 Generation	 Sequencing	 (NGS),	 also	 called	 high-throughput	 sequencing,	 is	 a	
powerful	 tool	 to	 investigate	many	 inherited	human	diseases.	Since	 the	appearance	of	 the	
first	 NGS	 instruments	 on	 the	 market	 in	 the	 first	 decade	 of	 the	 year	 2,000,	 impressive	
advances	have	enabled	an	 increasing	number	of	 applications,	 in	parallel	 to	a	decrease	 in	
costs	associated	with	this	technology.		
The	 whole-exome	 sequencing	 (WES)	 technique,	 contemplating	 the	 sequencing	 of	
exonic	 DNA	 regions,	 has	 become	 the	 chosen	 ‘routine’	 approach	 in	 most	 research	
laboratories;	nonetheless	it	is	used	with	an	increasing	extent	in	clinical	diagnostics.		
A	 more	 expensive	 but	 also	 more	 complete	 approach	 is	 called	 whole-genome	
sequencing	 (WGS).	 In	 contrast	 to	WES,	which	 investigates	 about	 2	%	 of	 an	 individual’s	
genetic	 information,	 WGS	 consists	 in	 determining	 the	 full	 sequence	 of	 an	 individual’s	
genome.	 	Moreover,	 this	 technique	allows	 the	 identification	of	 less	 “canonical”	mutations	
due	 to	 structural	 variations	 such	 as	 large	 deletions,	 insertions,	 duplications,	 inversions,	
translocations	and	copy	number	variations.	However,	due	to	the	generation	of	increasingly	
large	 amounts	 of	 raw	 files,	 analysis	 of	 any	NGS	 data	 requires	 an	 adapted	 computational	
pipeline	that	is	relevant	for	the	phenotype	studied.	
	
The	general	workflow	of	NGS	 consists	 in	an	 initial	 step	named	 ‘library	 construction’.	
During	this	first	phase,	the	DNA	is	fragmented	into	smaller	pieces	that	are	then	ligated	to	
special	 adapters.	 In	 the	 case	 of	 WES,	 the	 fragmented	 DNA	 is	 captured	 by	 targeted	
hybridization,	 using	 probes	 specifically	 designed	 for	 exonic	 sequences,	 and	 it	 is	 then	
amplified.	 In	contrast,	 for	WGS	the	 library	construction	does	not	require	hybridization	to	
probes,	avoiding	 the	risk	of	non-uniform	coverage.	Further	comparison	of	WGS	and	WES	
techniques	are	discussed	in	project	4	–	called	NEXOME.	
The	 simplest	 high-throughput	 sequencing	 strategy	 is	 through	 single-read	 sequencing,	
during	which	 the	 sequencer	 reads	 DNA	 fragments	 only	 from	 one	 end.	 The	 length	 of	 the	
reads	is	variable,	depending	on	the	instrument	and	the	technique	used.	On	the	other	hand,	
in	paired-end	sequencing	the	DNA	sequences	are	read	in	both	directions	–	from	both	ends	







After	 sequencing,	 the	workflow	 consists	 in	 performing	mapping	and	variant	 calling.	
The	short	NGS	reads	are	mapped	to	the	reference	genome	using	an	appropriate	software	
(e.g.	Novoalign),	and	subsequently	the	variants,	i.e.	the	differences	between	the	reads	and	
the	 reference	 genome,	 are	 listed	 in	 a	 standard	 file	 format	 named	 vcf	 (variant	 calling	




in-house	 databases,	 impact	 at	 the	 protein	 level,	 degree	 of	 conservation	 of	 the	 involved	
amino-acids,	 prediction	 of	 the	 effect	 on	 splicing,	 prediction	 of	 deleteriousness	 from	
different	software,	and	other	 information	relevant	to	the	disease	of	 interest.	Additionally,	




to	 be	 considered	 for	 efficiently	 analyze	 the	 NGS	 data.	 In	 the	 case	 of	 rare	 diseases	 with	
Mendelian	 inheritance,	 consanguineous	
unions	dramatically	increase	the	probability	
for	 the	 offspring	 to	 be	 homozygous	 at	 any	
genetic	locus	(Figure	8)43.	Indeed,	very	rare	
recessive	 disorders	 are	 predominantly	
observed	 in	 small	 isolated	 towns,	 where	
parents	 are	 closely	 related,	 and	 in	 regions	
with	high	levels	of	endogamy.	In	this	typical	
case	 studies	 homozygosity	 mapping	 can	
provide	substantial	help	in	narrowing	down	
the	 number	 of	 candidate	 variants,	 by	
looking	 at	 the	 changes	 occurring	 in	 the	
mapped	 autozygous	 regions.	 Other	
approaches	 include	 family	 analysis,	
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Abstract
Hereditary retinal degenerations encompass a group of genetic diseases characterized by extreme clinical variability.
Following next-generation sequencing and autozygome-based screening of patients presenting with a peculiar, recessive
form of cone-dominated retinopathy, we identified five homozygous variants [p.(Asp594fs), p.(Gln117*), p.(Met712fs),
p.(Ile756Phe), and p.(Glu543Lys)] in the polyglutamylase-encoding gene TTLL5, in eight patients from six families. The two
male patients carrying truncating TTLL5 variants also displayed a substantial reduction in sperm motility and infertility,
whereas those carrying missense changes were fertile. Defects in this polyglutamylase in humans have recently been associ-
ated with cone photoreceptor dystrophy, while mouse models carrying truncating mutations in the same gene also display
reduced fertility in male animals. We examined the expression levels of TTLL5 in various human tissues and determined that
this gene has multiple viable isoforms, being highly expressed in testis and retina. In addition, antibodies against TTLL5
stained the basal body of photoreceptor cells in rat and the centrosome of the spermatozoon flagellum in humans, suggesting
a common mechanism of action in these two cell types. Taken together, our data indicate that mutations in TTLL5 delineate a
novel, allele-specific syndrome causing defects in two as yet pathogenically unrelated functions, reproduction and vision.
Introduction
Cone dystrophies (CDs) and cone-rod dystrophies (CRDs) are
rare heterogeneous retinal disorders with an estimated preva-
lence of "1:40,000 (1). They lead to severe visual impairment,
primarily or exclusively due to the degeneration of cone photo-
receptors. Patients experience progressive loss of visual acuity,
defective colour vision, photophobia, and have central scoto-
mas. Only later, as the disease progresses, in some cases loss of
peripheral vision may also occur (2,3).
The progressive degeneration of retinal photoreceptors in
CDs and CRDs is mostly nonsyndromic and has been associated
with multiple genetic causes, with at least 20 associated disease
genes (RetNet; http://www.sph.uth.tmc.edu/RetNet/; date last
accessed July 8, 2016). However, more than 75% of cases pre-
senting with dominant or recessive forms of these conditions
are genetically unsolved (4). Recent discoveries in CD molecular
genetics include the identification of pathogenic variants in the
tubulin polyglutamylase TTLL5 (Tubulin Tyrosine Ligase-Like
Protein 5) gene, found to cause retinal dystrophy in four British
families (5). This gene, like the 12 other members of the TTLL
superfamily, is involved in post-translational modifications of
a- and b-tubulin, which are components of the axonemes of
both cilia and flagella.
Interestingly, male mice with a defective TTLL5 display dra-
matically reduced fertility associated with defects in sperm mo-
tility (6). Most sperm tails of mutant mice were found to have
disrupted axonemes with loss of tubulin doublets and a signifi-
cantly decreased polyglutamylation in the upper and lower seg-
ments. No abnormal phenotype of retinal photoreceptors or of
cochlear cells was initially observed, based on histologic exami-
nation (6). A second study with a more thorough characterization
of the ocular phenotype in the same mouse model showed a de-
cline of electroretinographic (ERG) amplitudes for both rods and
cones in aged mice (20-22 mo). However, no microtubule defects
were found after examination of electron micrographs (7).
Ciliopathies represent a class of hereditary disorders involv-
ing deficiencies in ciliary and cilia-associated proteins, often af-
fecting a variety of tissues and organs (8). Due to the presence of
an immotile cilium in both rods and cones photoreceptors,
many ciliopathies display a retinal phenotype, either as part of
a syndromic condition (associated with hearing defects, renal
nephronophtisis, liver fibrosis, bone and/or brain anomalies) or
as the sole pathological sign (9–11).
Following the investigation of a cohort of patients displaying
CD or CRD, we identified mutations in TTLL5 that are associated
with both retinal degeneration and reduced sperm motility in
humans, possibly defining a novel syndromic ciliopathy.
Results
Clinical and molecular findings
Our research started with the molecular characterization of a
Swiss male patient (P1), aged 75 years, presenting with a late-
onset cone dystrophy (CD). He was the eldest of three brothers
and his parents were first cousins (Fig. 1, F1), without any his-
tory of ocular problems. The patient was first seen at the age of
33 years, when he first noticed blurred vision. His best corrected
Snellen visual acuity (BCVA) at that time was 0.6 in the right eye
and 0.8 in his left eye. Seven years later, his BCVA was still sta-
ble, but worsened when he was 53 years old, dropping dramati-
cally to 0.05 in the right eye and 0.08 in the left eye. He was also
complaining of a reduced dark adaptation. Twenty-two years
later his vision remained stable, with the patient using more of
his peripheral vision.
The clinical examination was typical of a cone dystrophy:
the fundus examination showed central foveal atrophy with
peripapillary hyperpigmentation and atrophy, while the periph-
eral retina was within normal limits (Fig. 2). The first ERGs (per-
formed when the patient was 56 years old) showed normal
scotopic responses, whereas photopic responses had severely
reduced amplitude. The following ERG testing, when the patient
was 70 years old, showed some rod involvement, with reduced
rod-specific b-wave. The 30-Hz flicker was undetectable.
Autofluorescent (AF) images at age 66 years (Fig. 2) showed cen-
tral hypofluorescence corresponding to atrophy, surrounded by
a large hyperfluorescent ring. AF imaging at age 72 indicated
that the ring mildly increased in diameter, and so did the area
of hypofluorescence (Fig. 2). Kinetic visual field tested at this
later age showed mild constriction and central scotoma in both
eyes.
The DNA of the patient was first screened for mutations in
known disease genes. Following the negative output of a panel-
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based Next-Generation Sequencing screening [the IROme (12)],
we performed whole-genome sequencing (WGS) of the patient’s
DNA. This latter procedure resulted in more than 4 million DNA
variants with respect to the human reference genome (Build
hg19). These were evaluated by the use of an internal in-silico
pipeline assessing their frequency in the general population,
quality, etc. (Supplementary Material, Table S1), as well as their
presence within autozygous regions (Supplementary Material,
Fig. S1). At the end of this process, we were left with 19 variants
(7 in autozygous regions), including c.1782delT in TTLL5 (Fig. 3),
a gene known to be involved in microtubule posttranslational
modifications and associated with ciliary microtubule stabiliza-
tion (13). The variant was in exon 20 and consisted of a 1-bp de-
letion causing a frameshift starting from codon 594 and
terminating with the creation of a premature stop triplet 29 co-
dons downstream [p.(Asp594Glufs*29)]. It was also not detected
in the genome of 400 healthy controls from the same geo-
graphic region of Switzerland [data from the CoLaus study (14)],
and from publicly available databases [ExAC (15), dbSNP (16)].
Importantly, this DNA change localized to a region of chromo-
some 14 (75,986,579-80,875,911, Build hg19) showing clear auto-
zygosity (Supplementary Material, Fig. S1) in P1’s genome.
Because of the possible involvement of TTLL5 in extra-
ocular ciliary functions, the patient underwent more detailed
clinical examinations. To assess the presence of additional sub-
tle abnormalities in organs known to be affected by ciliopathies,
he was evaluated for both renal and otorhinolaryngological
functions. He did not display the classical clinical features of re-
nal ciliopathy (no polyuria/polydipsia), but chronic renal insuffi-
ciency without proteinuria (stage G3aA1) (17) was identified,
associated with low-grade chronic anemia. By ultrasound, the
size of the kidneys appeared to be preserved, but a small asym-
metry was noted (9.6 cm on the left vs. 10.7 cm on the right
side), without significant renal artery stenosis. No cysts were
visible and no biopsy was performed. Altogether, the renal fea-
tures were consistent with age-related decreased renal func-
tion, but low-grade and late appearance nephronophtisis
cannot be fully excluded. The observed minor sensorineural
hearing loss, and loss of some high frequencies, was compatible
with the natural course of hearing about a person of the age of
the subject (Supplementary Material, Fig. S2). The clinical exam-
ination and patient’s history did not reveal any upper airway
pathology necessitating further investigations for impaired
mucocillary function in the sinus or the bronchi. The patient re-
ported a history of infertility due to reduced sperm motility, di-
agnosed when he was in his late 20’s. He could not have
offspring and adopted two children. Following our findings, a
new semen analysis was performed at age 75, revealing azoo-
spermia, a sign that nonetheless could simply be related to the
difficulty in obtaining an ejaculate at his current age.
Based on these findings, we extended our analyses to a num-
ber of additional cohorts of 365 patients with CD and CRD from
Switzerland, Sweden, Greece, The Netherlands, and Britain. In a
Swedish male patient of Iraqi descent (P2), we identified the ho-
mozygous nonsense variant c.349C>T;p.(Gln117*) by targeted
Sanger sequencing of TTLL5 (Figs. 1, F2; 3). Again, this variant
was absent from controls and publicly available databases.
Although the patient did not report any history of consanguin-
ity, the occurrence of this extremely rare variant in a homozy-
gous state suggests the presence of residual consanguinity or of
a geographical founder effect, which was not tested at the ge-
nome level. The patient, aged 46 years, reported no family his-
tory of similar visual impairment. Fundus examination revealed
degenerative changes, especially in the posterior pole, but more
normal features in the periphery. Visual field analysis by
Goldmann perimetry showed residual fields in the periphery,
but a large central scotoma. Full-field ERG demonstrated resid-
ual cone and rod response, consistent with a diagnosis of cone-
rod degeneration. In addition to these signs and symptoms typi-
cal of CRD, the patient had high myopia (Table 1). This subject
was also infertile, but had been able to have a child by in vitro
fertilization. His semen analysis revealed a normal spermatozoa
count but, similar to P1, reduced sperm motility. He also had
morphologically normal spermatozoa for 5% of the count, over
three independent assays.
Following autozygome-based analysis (Supplementary
Material, Fig. S1), we identified homozygous mutations in three
additional patients from the Netherlands (Fig. 1, F3–5). All of
them were diagnosed with CD, with full-field ERGs showing re-
duction of cone function but preserved rod responses (Table 1).
Similar to the cases described above, the female patient P3 had
a TTLL5 truncating mutation, c.2132_2133insGATA;p.
(Met712IleAspfs*15), resulting in a premature termination co-
don. The other two patients (P4, and P5) were males and
both carried homozygous missense mutations, namely c.
1627G>A;p.(Glu543Lys) and c.2266A>T;p.(Ile756Phe),
Figure 1. Pedigrees from families with pathogenic TTLL5 variants. The probands are: subject P1 [II:3, family F1; c.1782del;p.(Asp594Glufs*29)], subject P2 [II:4, family F2;
c.349C>T;p.(Gln117*)], subject P3 [II:3, family F3; c.2132_2133insGATA;p.(Met712IleAspfs*15)], subject P4 [II:4, family F4; c.1627G>A;p.(Glu543Lys)], subject P5 [II:4, fam-
ily F5; c.2266A>T;p.(Ile756Phe)], and subject P6 [IV:14, family F6; c.1627G>A;p.(Glu543Lys)].













respectively (Fig. 3). Following colour vision testing, substantial
mistakes were made in all three colour axes. All patients had a
myopic refractive error, but none of them showed any addi-
tional extraocular symptoms. In particular, they did not report
any fertility problems, and both male patients had offspring.
Finally, a male patient (P6) of Pakistani origin was screened
by whole-exome sequencing (WES). He was a member of a con-
sanguineous pedigree that included six additional individuals
with high myopia and an acquired CD or CRD with loss of cor-
rected visual acuity from the second decade onwards (Fig. 1, F6).
In this case as well, a homozygous mutation in TTLL5 was iden-
tified within an autozygous region in chromosome 14
(Supplementary Material, Fig. S1). It was the same missense de-
tected above [c.1627G>A;p.(Glu543Lys), Fig. 3], which perfectly
co-segregated with the disease in the three affected and two un-
affected individuals for which DNA samples were available.
Figure 2. Fundi of index patient P1. Autofluorescence imaging of the right (A) and left (B) eye at age 66 years, showing a distinctive pattern of abnormalities, including a
hyperfluorescent ring and hyperfluorescent area at the fovea surrounded by patchy hypofluorescence in both eyes. Hypofluorescence around the optic nerve was also
present. The same images, obtained 6 years later (C,D), showed an increase of hypofluorescent areas within the ring and a mild enlargement of the hyperfluorescent
ring in both eyes. Composite pictures of the fundi at age 72, showing atrophic areas around the fovea and around the optic nerve (E,F). Peripheral retina was within nor-
mal limits.













Of note, in addition to retinal dystrophy, all patients from this
pedigree reported high to very-high myopia (-5 to -22 diopters)
(Table 1). None of the patients reported fertility problems, and
indeed patient P6 had five children.
TTLL5 RNA isoforms and expression in different tissues
According to publicly-available databases, TTLL5 produces six
protein-coding and alternatively spliced isoforms (transcripts
001, 002, 003, 016, 017, 018 of the Ensembl database GRCh37, re-
lease 84), presenting a rather widespread expression throughout
different tissues and organs (UniGene). To gain insights into
this topic, we investigated the composition and abundance
of TTLL5 transcripts in a panel of cadaveric organs and tissues
(Fig. 4).
Our data confirmed that TTLL5 has an extremely variable ex-
pression pattern, both in terms of isoforms and of presence in
various tissues. However, qualitative and quantitative assess-
ment of all transcripts revealed that expression of the canonical
isoform 001 was overwhelmingly more abundant (more than
40-fold higher than the average of the remainder) and that ex-
pression in the retina and testis represented !64% of TTLL5
presence across all tissues and organs examined (31 and 33% in
testis and retina, respectively; Fig. 4). Interestingly, all muta-
tions identified in our cohort of patients affected isoform 001,
and individuals with inactivating mutations showed reduced
fertility (Table 1).
TTLL5 mRNA level in the index patient P1
Since mutations leading to premature termination codons trig-
ger nonsense-mediated mRNA decay (NMD) and result in no or
in short-lived transcripts (18), we analysed expression of TTLL5
in skin fibroblasts from patient P1, displaying retinal degenera-
tion and infertility. Quantitative real time PCR (q-PCR) resulted
in a dramatically reduced detection of the transcript of interest
as compared to a healthy control fibroblast mRNA (!10%; Fig. 4).
TTLL5 protein in ciliated fibroblasts,
retina, and spermatozoa
To better understand the role of TTLL5 with respect to the cellu-
lar cilium, we analysed control fibroblasts following serum
starvation, a procedure that induces ciliogenesis.
Immunofluorescence analysis revealed the clear localization of
TTLL5 at both centrioles (Fig. 5, panels A–D).
Subsequently, we performed immunofluorescence analyses
in the retina and sperm cells from rat and human, respectively
(Fig. 5, panels E-G). In agreement with previous results in mouse
and human (5), the anti-TTLL5 antibody decorated the inner
segment of photoreceptors in proximity of the basal body and
the connecting cilium, suggesting that TTLL5 may in fact play
its functions at the base of the photoreceptor primary cilium.
Staining of mature human spermatozoa also indicated for
the first time a clear centrosomal localization of TTLL5, with no
overlap with the polyglutamylated a- and b-tubulin of the
flagellum.
Discussion
Both primary (or immotile) and motile cilia play crucial roles in
the normal function of most tissues of the human body. These
tiny hair-like organelles participate in a wide range of cellular
functions during development, tissue morphogenesis and ho-
meostasis. It is therefore not surprising that mutations in ciliary
genes are often associated with a broad range of conditions,
classified as ciliopathies, either involving single organs or caus-
ing syndromic phenotypes (8). Some examples of diseases af-
fecting primary cilia are polycystic kidney disease, Usher
syndrome, retinitis pigmentosa, Bardet-Biedl and Joubert syn-
dromes (19–22). On the other hand, motile cilia defects have
been shown to be causative for Kartagener syndrome and allied
diseases, collectively grouped under the disease spectrum of
primary ciliary dyskinesias.
Cilia and flagella, highly conserved in their core structure,
are ancestral organelles composed of more than 650 proteins





Figure 3. Mutation diagram of the TTLL5 protein (A), and corresponding cDNA. Red and green dots indicate truncating and missense mutations, respectively. Exons are
numbered and drawn to scale (B) with respect to the protein sequence. The TTL domain responsible for polyglutamylation activity is indicated. Chromatograms of the
mutations identified (C), compared to their relevant wild type sequences (D).
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microtubules, a- and b-tubulin, are subject to post-translational
modifications, accomplished by enzymes catalyzing different
reactions such as the generation of D2-tubulin, acetylation (24),
tyrosination (25), polyglutamylation (26) and polyglycilation
(27,28). Among members of the TTLL superfamily there are glu-
tamylases and glycilases (29–31). TTLL5 initiates the formation
of side chains within the C-terminal tail of a- and b-tubulin,
with a preference for a-tubulin (32), and current models indicate
that the role of polyglutamylation is to provide the necessary
conditions for proper MT-MAPs (microtubule and microtubule-
associated proteins) interactions. Studies have shown that poly-
glutamylation exerts differential regulation by selectively re-
cruiting different MAPs: MAP1B, MAP2, tau, and neuronal
kinesins have higher affinity for tubulins with 1-3 glutamyl
units, whereas MAP1A has higher affinity for longer side chains
(25,26,28). Moreover, it has been shown that masking polygluta-
mylated sites with a specific anti-polyglutamylated tubulin an-
tibody (GT335) affects the amplitude of flagellar beating in sea
urchin sperm axonemes, suggesting a key role of polyglutamy-
lated sites for interaction with ciliary dyneins (33). Centriole sta-
bility was also shown to be influenced by the degree of
polyglutamylation, and GT335 antibody-loaded HeLa cells
showed a complete transient disappearance of the centriole
pair (13). Finally, members of the TTLL family, Ttll3 and Ttll6,
play a role in cilia structure and motility in zebrafish (34). All
TTLL proteins have a preference for either a- or b-tubulin and
participate to either initiation or elongation of the polyglutamyl
side chain. TTLL5, together with TTLL4 and TTLL7, initiates
polyglutamylation, while other members function in the elon-
gation of the polyglutamyl side chain or in the initiation or the
elongation of polyglycylation.
Specific patterns of modifications on microtubules might be
responsible for various functions. In the case of polyglutamyla-
tion, the side chains are built within the carboxy-terminal tail
of tubulin, where the binding sites of motor and MT-associated
proteins (MAPs) are also found. Thus, it is plausible that the in-
teraction of MTs with such proteins might depend on specific
patterns of modifications (35). Additional studies highlighted
the importance of polyglutamylation for the proper beating of
airway cilia (36), as well as for providing a molecular traffic sign
required by motor proteins in order to maintain continuous
synaptic transmission (37). Major evidence of the implication of
polyglutamylation in photoreceptor ciliary function was re-
cently reported (7), showing that Ttll5-/- mice developed a simi-
lar retinal phenotype to Rpgr-/- mice, a known mouse model for
retinitis pigmentosa. In addition, Ttll5-/- mice display strongly
reduced glutamylation of RPGRORF15, a retina-specific variant of
RPGR (38). Altogether, current evidence strongly supports the
notion that the presence and length of polyglutamyl side
chains, not only on tubulin but also on other substrates, is cru-
cial for proper functioning of both motile and immotile cilia.
In our work we show that mutations in a gene involved in
the polyglutamylation of a-tubulin is associated with defects in
the retina and spermatozoa. Clinically, these molecular pheno-
types translate into cone-first CRD and reduced sperm motility,
likely due to the functional impairment of the primary cilium
and the flagellum, respectively. Our assumption is supported by
immunofluorescence data, demonstrating that TTLL5 localizes
at the basal body of the cilia in photoreceptors, as well as at the
base of the spermatozoal axoneme and in ciliated skin fibro-
blasts. Moreover, we reveal that the highest levels of expression
of the major TTLL5 protein-coding isoform is in the retina
and testis. It is also very interesting to note that, in terms of fer-
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genotype/phenotype correlation, which seems to be irrelevant
for retinal degeneration. In other words, the phenotype elicited
by TTLL5 pathogenic changes appears to depend on mutation
classes. Missense variants are seemingly associated with a non-
syndromic phenotype that is limited to the retina, whereas
inactivating mutations appear to disrupt the functions of both
photoreceptors and spermatozoa, thus defining a novel allele-
specific syndrome. Yet, three male patients with truncating
TTLL5 mutations were previously reported having offspring (5),
raising the possibility of variable expressivity or reduced pene-
trance of this class of mutations. In support of the latter hypoth-
esis, Ttll5 knockout mice display extremely reduced but
not completely abolished fertility (6). Alternatively, this geno-
type/phenotype correlation in our cohort could also be coinci-
dental. The association of TTLL5 mutations with severe
myopia is another intriguing hypothesis that warrants addi-
tional investigation in a larger cohort of patients, especially
given the complex pattern of inheritance of nearsightedness in
humans.
In conclusion, we show that mutations in TTLL5 are associ-
ated with a newly-defined syndrome affecting vision and the
male reproductive system. Despite the fact that cilia and flagella
have different morphologies and functions, they may share
similar physiological mechanisms, and the enzymatic reaction




Patient P1 was recruited from the Jules Gonin Ophthalmic
Hospital (Lausanne, Switzerland); and patient P2 from the
Department of Ophthalmology of Lund University Hospital
(Lund, Sweden). Patients P3, P4 and P5 were recruited from the
Radboud University Medical Center (Nijmegen, The
Netherlands) and the Erasmus University Medical Center
(Rotterdam, The Netherlands). Patients P6-8 were sampled by
author MMK, an ophthalmologist based at St James’s University
Hospital (Leeds, England), while on a field trip to Pakistan. DNA
of all subjects was extracted from peripheral blood leukocytes.
A control sperm sample was provided by a healthy donor. Our
research has been conducted in accordance with the tenets of
the Declaration of Helsinki and was approved by the
Institutional Review Boards of our respective Organizations.
A B C
Figure 4. Relative expression of TTLL5 isoforms and their expression. TTLL5 has six known alternative transcripts (001, 002, 003, 016, 017, and 018), resulting from the
splicing of the exons indicated here in dark grey (A). Their expression within seven different human tissues, measured by quantitative real time PCR, is indicated by
both numerical values and shades of grey (B). Although all isoforms seem to be widely expressed, isoform 001 is the most prominent one, among all tissues considered
(‘Total’ column). Asterisks show the position of the mutations identified in this work. TTLL5 isoform 001 expression in fibroblasts of the index patient P1 vs. a control,
by quantitative PCR (C). TTLL5 mRNA amounts were normalized with respect to the housekeeping gene HPRT1.
Figure 5. Immunofluorescence staining of ciliated control human skin fibroblasts (A-D). TTLL5 co-localizes with acetylated tubulin at the centrioles, as indicated by ar-
rowheads (C,D). Immunofluorescence in rat retina sections (E, and magnified cilium in F) and in control human spermatozoon (G). TTLL5 decorates the basal body in
photoreceptors and the centrioles in spermatozoa. Scale bars: A-E, 5 mm; F, 1 mm; G, 20 mm.













For patients P1-5, ophthalmologic examination included assess-
ment of BCVA, slit-lamp examination, funduscopy, fundus pho-
tography, and optical coherence tomography. Full-field ERGs
were also recorded, as prescribed by the International Society
for Clinical Electrophysiology of Vision (ISCEV).
For patients P6-8, ophthalmologic assessment was limited to
slit-lamp examination and fundus inspection using direct and
indirect ophthalmoscopy through dilated pupils. Owing to the
non-hospital setting, electrodiagnostic and other testing was
not available. Visual acuity was recorded together with a history
of nyctalopia or photoaversion.
Semen analysis was carried out for patients P1 and P2 by
standard procedures of andrology laboratories, and according to
WHO guidelines (39). For P1 patient, two Leja chambers (Leja)
filled with 6 ml of semen were entirely scanned under phase
contrast microscopy to confirm the absence of spermatozoa.
Additional clinical features were assessed only for patient P1,
due to substantial problems in getting back to the other pro-
bands. These tests included a thorough otorhinolaryngologic
examination assessing structure and function of the nasopha-
ryngeal mucosa, the ear canal and the hearing (by pure-tone au-
diometry), as well as a full renal examination, including a
complete checkup of renal function, urine and blood analysis,
assessment of blood pressure, and ultrasonography. Analyses
involving other tissues and organs known to be involved in
other ciliopathies were not performed due to a negative clinical
history: normal body mass index, no respiratory complains, no
metabolic disturbance and no skeletal abnormalities.
Whole-genome and whole-exome sequencing
WGS in the Swiss index patient P1 was performed using 4 mg of
DNA. Sequencing was performed by Complete Genomics Inc.
(Mountain View, CA, USA), as described previously (40). Genetic
variants were identified using v2.0 of the Complete Genomics
pipeline (41). WES was performed for proband P6 using 3 mg of
DNA. Protein-coding regions were captured using the SureSelect
All Exon v4 kit (Agilent) and paired-end sequencing was per-
formed using the Illumina HiSeq 2500 platform. Single nucleo-
tide variants and small insertions or deletions were detected
using the Genome Analysis Tool Kit (GATK v2.4.7) software
package, using the Best Practice Guidelines identified by the de-
velopers (42). The pathogenicity of genetic variants detected
through WGS and WES were assessed after functional annota-
tion through ANNOVAR (43).
Homozygosity mapping
Genomic regions with high homozygosity were determined us-
ing the free web-based tool HomozygosityMapper (44).
Mutation screening
Primer pairs for TTLL5 exons and flanking intron boundaries
were designed using the CLCbio Genomics Workbench (Qiagen,
Supplementary Material, Table S2). PCR amplification was per-
formed in a 20 ll total volume containing 10 ng genomic DNA,
1x GoTaq buffer, 0.1 mM dNTPs, 10 lM of each primer, and 5 U/ll
of GoTag polymerase (Promega). PCR products were purified
(ExoSAP-IT, USB) and a sequencing reaction was performed in a
total volume of 5 ll using 1 ll primer 3.3 mM, 0.5 ll BigDye
Terminator v1.1, and 1 ll of the provided Buffer (Applied
Biosystems).
Antibodies
Commercial goat polyclonal anti-TTLL5 antibody (Santa Cruz
Biotechnology Inc), raised against a peptide mapping near the
C-terminus of TTLL5 human origin, was used at a 1:100 dilution.
Mouse monoclonal anti-centrin clone 20H5 antibody was
purchased from Millipore and used at a dilution of 1:1000. Anti-
polyglutamylated tubulin GT335 and monoclonal anti-
acetylated tubulin antibodies were provided by Dr C. Janke
(Institut Curie, Orsay, France) and purchased from Sigma-
Aldrich, respectively. Secondary donkey anti-goat antibodies
conjugated with Alexa Fluor 488 were purchased from
Invitrogen and secondary goat anti-mouse antibodies (Life
Technologies) were conjugated with Alexa Fluor 594 (1:1000).
Fibroblast immortalization and culture
Primary skin fibroblasts were immortalized with exogenous
hTERT by the use of pLOX-TERT-iresTK (45) and grown in
DMEM(1x)þ 1g/L D-glucose L-Glutamine Pyruvate (Gibco), sup-
plemented with 10% FBS, 1% penicillin-streptomycin, and 1%
fungizone, adapted from previously published protocols (46).
Immunofluorescence
Immunofluorescence was performed for TTLL5 localization in
human control spermatozoa and rat retinal sections. The sperm
staining procedure used was adapted from a previously pub-
lished protocol (47). After washing five times with PBS 1X in a
15 ml Falcon tube and centrifugation steps of 5’ at 800g, all at
room temperature (RT), the semen pellet was resuspended and
fixed with 4% (v/w) PFA in PBS, and incubated for 30 min on ice.
The sample was then washed three times with PBS and stored
at 4 "C for future use. The immunostaining procedure used 20 ml
aliquots of fixed sperm cells, transferred to a 1.5 ml Eppendorf
tube. Blocking was done for 30 min at RT in 100 ml PBS contain-
ing 3% (w/v) BSA (PBSA). Primary antibody incubation was per-
formed with specified dilutions in 100 ml PBSA, overnight at 4 "C.
Samples were washed three times with PBS containing 0.1%
(v/v) TX100 (PBST). Secondary antibody incubation for 30 min
was carried out at RT in 100 ml PBSAT [PBST containing 3% (w/v)
BSA and 0.1% (v/v) TX100]. After three washes with PBST and
two washes with PBS the final pellet was resuspended in PBS
and 5 ml were placed on a slide. 5 ml DAPI vectashield were added
to the sample, which was then coverslipped and fixed with nail
polish.
Unfixed Sprague-Dawley rat eyes and C57BL/6J mouse eyes
were isolated and soaked for 3 h in PBS containing 30% sucrose.
Eyes were embedded in Yazulla medium (30% egg albumen and
3% gelatin in water) and cryosectioned (12 mm) onto Superfrost
Plus slides (Thermo Scientific). Sections were washed three
times with PBS and a stepwise procedure was followed similar
to that described for sperm immunostaining, the only differ-
ence being that this was carried out on the slide and with lower
volumes.
Quantitative real time PCR
Primer pairs used for q-PCR are listed in Supplementary
Material, Table S3. The q-PCR product was visualized on 1%
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agarose gel to verify the primer’s specificity. A standard curve
using a control cDNA template prepared from human normal
tissues total RNA (BioChain) was used to test the efficiency of
each primer pair. HPRT1 was used as a normalization control, as
described (48). Amplification was performed using the SYBR
Green PCR Master Mix (Applied Biosystems).
Supplementary Material
Supplementary Material is available at HMG online.
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We	 investigated	 the	 genetic	 cause	 for	 the	 phenotype	 of	 three	 children	 from	 two	
unrelated	Italian	families	presenting	with	a	previously-unrecognized,	seemingly	autosomal	
recessive	disorder	that	included	Leber	congenital	amaurosis	(LCA),	sensorineural	hearing	





analysis	 by	 RNA	 sequencing	 on	 fibroblasts	 from	 patients	 vs.	 controls	 revealed	 a	 4-fold	
downregulation	 of	 the	 LCA-associated	 gene	NMNAT1,	 residing	 in	 the	 shared	 autozygous	






no	 patient	 with	 disruptive	 homozygous	 variants	 has	 ever	 been	 described,	 and	 murine	




patients,	 presumably	 causing	 a	 strong	 but	 not	 complete	 reduction	 of	 enzymatic	 activity,	
may	 therefore	 result	 in	 an	 intermediate	 phenotype,	 characterized	 by	 LCA	 with	 skeletal	
dysplasia.	 We	 performed	 long	 read	 whole-genome	 sequencing	 to	 precisely	 define	 this	




LCA	 is	 considered	 to	 be	 the	most	 severe	 form	 of	 inherited	 neurodegenerative	 retinal	
disease,	with	an	incidence	of	approximately	1	in	80,00044.	Its	distinctive	feature	is	the	early	
age	 of	 onset.	 LCA	 patients	 usually	 display	 in	 the	 first	 years	 of	 life	 a	 severe	 and	 rapidly	
progressive	 macular	 degeneration	 leading	 to	 central	 atrophy,	 with	 the	 appearance	 of	
congenital	coloboma	and	atrophy	of	the	optic	nerve45.		
Syndromic	LCA	is	rare,	and	to	date	only	two	genes	have	been	described	as	causative	for	
LCA	 with	 additional	 manifestations.	 Autosomal	 dominant	 inheritance	 of	 loss-of-function	
variants	in	the	OTX2	gene	were	associated	with	early	onset	retinal	degeneration	and	short	
stature.	 OTX2	 has	 been	 assigned	with	multiple	 roles,	 from	 development	 and	 function	 of	
both	the	RPE	and	the	neural	retina,	as	well	as	in	the	pituitary	gland46.	In	the	literature,	two	
syndromic	LCA	cases	were	described	in	concomitance	with	renal	features,	these	symptoms	
are	 collectively	 resumed	 under	 the	 name	 of	 Senior	 Loken	 syndrome	 (OMIM:	 266900)47.	





the	 individual	 phonotypes	 detected	 in	 these	 patients,	 to	 date	 no	 study	 has	 described	 a	






of	 nicotinamide	 adenine	 dinucleotide	 (NAD)56	 (Figure	 1),	 catalysing	 the	 condensation	 of	
nicotinamide	mononucleotide	 (NMN)	 or	 nicotinic	 acid	mononucleotide	 (NaMN)	with	 the	
AMP	moiety	of	ATP	to	form	NAD	or	Nicotinic	acid	dinucleotide	(NaAD).	The	coenzyme	NAD	
is	consumed	 in	hundreds	of	pathways,	as	 for	 instance	PARPs	 function	 in	DNA	repair	and	
cell	 death,	 and	 for	 Sirtuin	 1	 (SIRT1)	 action	 in	 the	 regulation	 of	 proliferation	 and	
metabolism.	
In	 this	work,	we	applied	an	 integrated	approach,	combining	short-	and	 long-read	NGS,	
RNAseq,	 as	well	 as	 functional	 studies,	 to	 determine	 the	 genetic	 elements	 leading	 to	 this	
previously-undescribed	pathology.	Our	results	led	to	the	identification	of	a	DNA	structural	
















This	 study	 has	 been	 conducted	 in	 accordance	 with	 the	 tenets	 of	 the	 Declaration	 of	








coding	 regions	 were	 captured	 using	 the	 HiSeq	 Rapid	 PE	 Cluster	 Kit	 v2	 and	 an	 Illumina	
HiSeq	2500	instrument	was	used	for	paired-end	sequencing.	Single	nucleotide	variants	and	
small	 insertions	 and	deletions	were	detected	using	 the	Genome	Analysis	Tool	Kit	 (GATK	
v4.0)	software	package,	using	the	Best	Practice	Guidelines	identified	by	the	developers	57.	
The	pathogenicity	of	the	detected	genetic	variants	was	assessed	after	functional	annotation	
through	 ANNOVAR58.	 Shared	 regions	 of	 homozygosity	 and	 common	 haplotypes	 for	 each	





control	 using	 trizol;	 kit	 and	 protocol	 from	Direct-zolTM	 RNA	MiniPrep	 (ZYMO	Research).	
RNA	 libraries	 were	 prepared	 by	 a	 service	 provider	 (Fasteris,	 Geneva,	 Switzerland)	 and	
single-read	RNA	sequencing	was	performed	using	an	Illumina	HiSeq	2500	instrument.		
Fastq	 files	 were	 analysed	 with	 both	 the	 CLCbio	 Genomics	Workbench	 (Qiagen)	 and	 the	
publicly	 available	 pipeline	 from	 RNAcocktail59.	 Raw	 Fastq	 files	 of	 27	 other	 control	 skin	







patient	 or	 control	 cDNA	 template	 prepared	 from	primary	 skin	 fibroblast’s	 RNA.	 Prior	 to	
sample	measurements,	 efficiency	of	 each	primer	pair	was	 tested	using	 a	 standard	 curve.	
Reference	controls	were	selected	according	 to	 their	stability	 throughout	 the	samples,	 the	
most	stables	being	TBP,	GAPDH	and	ACTB.	Normalization	was	done	using	a	geometric	mean	
of	the	Ct	values	of	the	three	reference	genes.	Amplification	was	performed	using	the	SYBR	











get	 enough	 coverage	 6	 SMRT	 flow-cells	 were	 sequenced	 on	 the	 PacBio	 RS	 II	 platform	
reaching	an	approximate	coverage	of	10x.	Reads	were	assembled	to	the	reference	human	




Cell	 lysates	 from	 cultured	 primary	 fibroblasts	 were	 prepared	 for	 each	 tested	 sample.	
After	 3	 washes	 with	 PBS,	 cells	 were	 scraped	 down	 from	 100mm	 dishes	 at	 ~90%	
confluence,	 and	were	 lysed	 using	 a	 the	 ReadiUse™	mammalian	 cell	 lysis	 buffer	 5X	 (AAT	
Bioquest).	The	 total	 relative	amount	of	both	oxidized	and	reduced	 forms	of	nicotinamide	
adenine	dinucleotides,	NAD+	and	NADH,	respectively,	was	measured	using	a	luminescence	
assay,	 the	 NAD/NADH-GloTM	 Assay	 kit	 (Promega).	 The	 values	 of	 detected	 luminescence	








Three	patients	 from	 two	 families	 residing	 in	 two	 geographycally	 distant	 cities,	Naples	
and	Genoa,	presented	with	similar	clinical	features,	altogether	seemingly	never	previously	




neurodevelopmental	 delay,	 attributable	 to	 brain	 anomalies	 that	 were	 identified	 through	














common	 to	 all	 three	 patients	 (Figure	 3).	 Furthermore,	we	 found	 that	 the	 haplotype	was	
identical	 in	 the	 two	 families,	 indicating	 the	 presence	 of	 a	 shared	 ancestor.	 This	 genomic	
fragment	 comprises	 40	 genes,	 none	 of	 which	 harboured	 mutations	 or	 rare	 variants	 in	
coding	 regions.	 Among	 them	 we	 could	 find	 genes	 putatively	 relevant	 to	 the	 phenotype	
investigated:	CAMTA1,	 associating	with	 cerebellar	ataxia	with	mental	 retardation	 (OMIM:	
614756);	RERE,	associating	with	neurodevelopmental	disorder	with	or	without	anomalies	
of	 the	 brain,	 eyes	 or	 heart	 (OMIM:	 616975);	 NMNAT1,	 involved	 in	 leber	 congenital	
amaurosis	 (OMIM:	 608553);	 and	 CTNNBIP1,	with	 to	 date	 no	 human	 disease	 association,	
but	known	 to	cause	short	 stature	
in	mice	when	overexpressed62.	Of	
those,	 only	NMNAT1	 is	 known	 to	
associate	 with	 a	 recessive	 mode	
of	 inheritance,	 the	 mode	 of	
genetic	 transmission	 likely	
























































































Homozygous Regions for UD−NA011−P2 patient







































































Homozygous Regions for 947−13 patient









































































RNA	 sequencing	 analysis	 showed	 that	 21	 transcripts	 were	 significantly	 differentially	
expressed	(Figure	4)	 in	our	three	patients	compared	to	28	healthy	controls.	Among	them	
the	LCA-associated	gene	NMNAT1,	the	only	one	residing	in	the	autozygous	interval	shared	
by	 the	 three	patients.	 Statistical	 analysis	proved	 significant	downregulation	by	a	5.4-fold	
factor	(p-value	1.3x10-4).	Following	this	finding,	we	questioned	ourselves	about	the	reason	
of	 this	reduced	expression,	given	that	the	WES	data	did	not	reveal	any	candidate	variant,	
nor	 we	 could	 see	 any	 evident	 abnormalities	 in	 coverage.	 Thus,	 we	 performed	 Sanger	
sequencing	on	NMNAT1	regulatory	regions	(Figure	5),	verifying	sequences	of	the	promoter	
and	two	upstream	enhancer	segments	but,	again,	no	anomalies	were	 found.	Similarly,	we	
could	 attest	 that	 the	 close	 CTCF	 upstream	 insulator	 was	 intact,	 proving	 unlikely	 any	
disruption	of	the	topologically	associated	domain	(TAD)	in	this	region.	
Moreover,	 among	 the	differentially	 regulated	genes,	we	observed	significant	 reduction	
in	 the	 expression	 of	 the	 gene	 encoding	 for	 a	ATP-dependent	 potassium	 channel	 subunit,	
KCNJ8.	 This	 gene	 has	 been	 associated	 to	 Cantu	 syndrome	 (hypertrichotic	
osteochondrodysplasia,	 OMIM	 239850)	 with,	 at	 a	 first	 glance,	 similar	 features	 to	 our	
patients’	 manifestations	 (skeletal	 dysplasia,	 coarse	 facial	 features)	 and	 additional	






















Validation	 of	 the	 RNA	 sequencing	 results	 using	 RT-PCR,	 brought	 to	 our	 evidence	 the	
presence	 of	 aberrant	 isoforms	 of	NMNAT1	mRNA.	 Sanger	 sequencing	 proved	 that	 these	
transcripts	 harboured	 either	 partial	 retention	 of	 intron	 3,	 duplication	 of	 exon	 4	 or	
duplication	both	exon	4	and	part	of	exon	5.	The	part	of	exon	5	retained	consists	in	the	first	
278	 bases,	 until	 the	 weak	 donor	 splice	 consensus	 “ttgGTACCA”.	 Human	 Splice	 Finder	
assigns	a	score	of	70	(ranges	between	0	and	100),	and	MAXEntScan	calculates	a	score	of	
4.88	using	the	maximum	dependence	decomposition	model	(ranges	between	-10	and	10).	
Quantitative	 RT-PCR	 with	 wildtype-	 and	 abnormal	 isoform-	 specific	 primers	 served	 to	
























event	 was	 mediated	 by	 recombination	 between	 these	 two	 Alu	 elements.	 Moreover,	
genome-wide	 single	 nucleotide	 variants	 (SNVs)	 and	 structural	 variants	 (SVs)	 analysis	 of	



























NMNAT1	 involvement	 in	 NAD+	 biosynthesis	 brought	 us	 to	 investigate	 any	 change	 in	















To	 date,	 the	 disease	 mechanism	 through	 which	 loss-of-function	 variants	 in	 NMNAT1	
cause	 LCA	 are	 not	 clear.	 In	 human,	 NMNAT1	 together	 with	 NMNAT2	 and	 NMNAT3	 are	
responsible	for	the	conversion	of	NaMN	and	NMN	into	NAD,	an	essential	metabolite	for	a	
wide	 range	 of	 biological	 processes.	 Each	 of	 the	 NMNAT	 enzymes	 localizes	 to	 a	 specific	
subcellular	 compartment.	 NMNAT1	 is	 a	 nuclear	 protein,	 whereas	 NMNAT2	 and	 3	 are	
localized	to	the	Golgi	complex	and	the	mitochondria,	respectively64.		The	three	isoforms	are	
thought	to	have	compartment-specific	functions	rather	than	functional	redundance,	first	of	





in	 the	 section	of	 the	 axon	distal	 to	 the	 lesion,	 is	 slowed	down	by	overexpressing	Wlds,	 a	
chimeric	version	of	Nmnat165–69.	Therefore,	NMNAT1	was	considered	of	 interest	 to	study	
potential	 therapeutic	 targets	 in	 the	 NAD	 biosynthesis	 pathway	 to	 fight	 neurological	
disorders.		
Interestingly,	 the	 Nmnat1	 knockout	 mice	 die	 before	 birth,	 indicating	 that	 the	
extranuclear	NMNAT	 isoforms	 cannot	 compensate	 for	 its	 loss66,67,69.	Nevertheless,	mouse	
models	 carrying	 missense	 mutations	 recapitulate	 the	 human	 LCA	 phenotype70.	
Noteworthy,	among	the	numerous	reported	human	pathogenic	NMNAT1	variants,	we	never	









to	 be	 found	 in	 the	 shared	 interval	 of	 chromosome	1.	 The	 genomic	 rearrangement	 in	 the	
NMNAT1	gene	 is	 certainly	 contributing	 to	 the	 disease	 manifestation.	 What	 needs	 to	 be	
clarified	 is	whether	this	particular	SV	in	NMNAT1	 is	responsible	for	the	whole	syndromic	




is	KCNJ8.	One	 particular	 variant	 in	 this	 gene	was	 associated	with	 the	 Cantu	 syndrome,	 a	
disorder	 partly	 resembling	 to	 the	 phenotype	 in	 our	 patients.	 However,	 KCNJ8	 was	
discarded	for	several	valid	genetic	and	clinical	reasons.	First,	because	the	gene	is	not	in	the	














The	 PacBio	 long-reads	 WGS	 allowed	 us	 to	 determine	 the	 precise	 breakpoint	 of	 the	
duplicated	NMNAT1	 fragment,	 as	well	 as	 the	 regions	 flanking	 this	 segment.	 The	 two	Alu	
elements	 identified,	AluSx	 and	AluSx3,	presenting	with	highly	homologous	sequences,	are	
very	 likely	 involved	 in	 the	mutational	 event	 at	 the	 origin	 of	 the	 duplication,	 creating	 an	
AluSx-AluSx3	 fusion	 element	 between	 the	 two	 copies	 of	 the	 duplicated	 fragment.	 Such	
rearrangement	 represents	 a	 non-allelic	 homologous	 recombination,	 consisting	 in	 a	
crossing-over	 occurring	 between	 non-equivalent	 sequences	 with	 high	 homology.	 This	
event	 can	 occur	 between	 sister	 chromatids	 in	 mitosis	 or	 between	 homologous	
chromosomes	during	meiosis,	and	can	result	in	deletion	or	duplication	events,	or	in	more	
complex	 chromosomal	 rearrangements.	 To	 date,	 Alu-mediated	 recombination	 has	 been	
associated	with	numerous	diseases71–74,	 including	two	LCA	cases50,	 for	whom	were	found	
Alu-mediated	 deletions,	 both	 coupled	 in	 compound	 heterozygosity	 with	 other	 missense	
changes.	
Nowadays,	with	 the	use	of	high	coverage	WES,	we	can	 likely	 find	rearrangements	 that	







Several	 mutations	 in	 the	 NMNAT1	 gene	have	 been	 shown	 to	 cause	 LCA44,45,49–51,53,54.	
However,	no	patient	with	disruptive	homozygous	variants	has	ever	been	described,	except	




to	 cause	 complete	 loss	 of	 NMNAT1	 enzymatic	 activity	 in	 vitro	 in	 transformed	 Hela	 cell	
lines48,64,75.	 Yet,	we	 do	 not	 know	what	 phenotype	would	 result	 in	 human	with	 this	 same	
homozygous	missense	mutation.		
Noteworthy,	non-coding	NMNAT1	variants	were	previously	 found	 in	 two	LCA	patients	
with	 homozygous	 single	 nucleotide	 substitutions	 in	 NMNAT1	 5’UTR,	 causing	 decreased	
NMNAT1	 mRNA	 levels	 in	 patients’	 lymphocytes,	 and	 decreased	 enzymatic	 activity	
(luciferase	assay)	in	human	retinal	pigment	epithelial	RPE-1	cells50.	We	hypothesised	that,	
since	 in	 these	 patients	 the	 NMNAT1	 protein	 sequence	 is	 preserved,	 residual	 wildtype	
function	could	be	retained,	limiting	the	phenotype	to	LCA	only.	






this	 lethality	 demonstrates	 that	 NMNAT2	 and	 NMNAT3	 cannot	 compensate	 the	 loss	 of	
NMNAT1	function.	
Both	in	vitro	and	in	vivo	mouse	studies	on	the	Wallerian	degeneration	mouse	model	wldS,	
overexpressing	 a	 fusion	 protein	 that	 incorporates	Nmnat1	 and	 the	 ubiquitination	 factor	
Ube4b,	 proved	NMNAT1	 to	 have	 a	 beneficial	 effect	 in	 neuronal	 protection	 after	 injury75.	
Additionally,	 it	 has	 been	 demonstrated	 that	 in	 vitro	 inactivation	 of	 NMNAT1	 enzymatic	




no	neuroprotective	effect69.	Altogether,	 these	 results	 suggest	 that	 the	benefic	outcome	of	
Nmnat1	 expression	 might	 be	 simply	 linked	 with	 its	 function	 in	 the	 production	 of	 NAD,	
however	it	remains	specific	to	the	fusion	protein	expressed	by	the	WldS	mice.	
On	 the	 other	 hand,	 we	 showed	 that	 whole	 cell	 extracts	 of	 patients’	 versus	 controls’	
fibroblasts	 do	 not	 have	 significantly	 lower	 quantities	 of	 total	 NAD/NADH.	 On	 this	 same	
note,	 it	 has	 been	 recently	 shown	 in	mouse	 that	modulation	 of	 the	 enzymatic	 activity	 by	
overexpressing	or	downregulating	NMNAT1,	was	not	associated	with	significant	alterations	
of	NAD	 levels78.	Altogether,	 these	data	open	 the	possibility	 for	 the	presence	of	additional	




associated	 variants	 showed	 large	 variability:	 some	 variants	 producing	 almost	 complete	
inactivation	(99.5%	p.Arg66Trp)	and	other	variants	milder	inactivation	(18.9	p.Arg237Cys)	
of	NMNAT148,79.	Interestingly,	in	line	with	our	hypothesis,	we	could	not	find	among	the	LCA	











In	 2017,	 described	 three	 patients	 with	 homozygous	 variants	 in	 two	 genes	 from	 the	
Kynurenine	pathway,	HAAO	and	KYNU,	genes	responsible	for	the	de	novo	synthesis	of	NAD	
from	tryptophan	(Figure	1).	Patients	showed	phenotypes	with	variable	impact	at	different	
levels,	 somehow	 similar	 to	 those	 identified	 by	 us:	 vertebral	 segmentation	 defects,	 short	
stature	 (skeletal	 dysplasia),	 sensorineural	 hearing	 loss,	 microcephaly,	 intellectual	
	82	
disability,	as	well	as	cardiac	and	renal	defects	(Figure	11).	Interestingly,	they	demonstrated	
that	 NAD	 levels	 in	 patients	 and	 in	mouse	models	with	 loss-of-function	KYNU	 and	HAAO	
were	reduced,	concomitantly	with	a	reduced	in	vitro	activity	of	both	enzymes.	We	therefore	
hypothesised	that	the	phenotype	resemblance	with	our	patients	may	rely	on	the	common	
participation	 of	 KYNU,	 HAAO	 and	 NMNAT1	 in	 the	 biosynthesis	 of	 NAD,	 and	 that	 the	
syndrome	in	our	patients	is	likely	due	to	the	deficiency	of	NMNAT1	activity.	Remarkably,	in	













In	 human,	 the	 final	 step	 of	 NAD	 biosynthesis	 is	 performed	 by	 the	 three	 isozymes,	
NMNAT1-3.	Considering	their	different	subcellular	localization	and	differences	in	structure	
and	 catalytic	 properties,	 these	 enzymes	 might	 be	 subject	 to	 differential	 regulation.	
Moreover,	 these	 enzymes	 could	 answer	 to	 the	 need	 of	 NAD	 in	 a	 compartment-specific	
manner.	As	we	verified	NAD	production	 in	our	patients	 in	whole	cell	 lysates,	 it	would	be	




of	 the	 nuclear	 production	 of	 NAD	 or	 to	 another	 yet	 unknown	 function	 of	 NMNAT1.	
Furthermore,	 we	 should	 evaluate	 NMNATs	 enzymatic	 activities	 by	 providing	 different	
quantities	 of	 NMN,	 the	 NAD	 precursor,	 in	 cell	 nuclear	 and	 cytoplasmic	 extracts.	
Comparatively,	 NAD	 levels	 and	 NMNAT1	 activity	 of	 the	 homozygous	 Trp169*	 patient	
would	 answer	 to	 the	 question	 whether	 the	 cause	 of	 LCA	 and/or	 syndromic	 features	 is	
related	to	a	change	in	NAD	production.	Finally,	it	would	be	interesting	to	generate	the	same	
duplication	in	a	mouse	model	in	order	to	see	if	it	phenocopies	the	human	disease.	Finding	
other	 families	 with	NMNAT1	 variants	 with	 a	 similar	 impact	 to	 what	 we	 observe	 in	 our	
patients	would	be	a	 final	 confirmation	of	our	 severe	 intermediate	phenotype	hypothesis.	













other	 colleagues	 of	 Prof	 Rivolta’s	 lab.	 I	 personally	 took	 part	 to	 the	 project	 from	 the	
beginning	 and	 later	 took	 charge	 of	 directing	 the	 analysis.	 Together	 with	 Beryl	 Royer-
Bertrand	we	initially	analysed	all	WES	data	of	negative	exomes.	Afterwards,	 I	carried	out	
most	of	the	analysis	of	WGS	data,	I	analyzed	all	structural	variants,	performed	and	explored	
the	 autozygome,	 and	 discussed	 with	 the	 ERDC	 members	 about	 the	 possible	 candidate	




This	 work	 aimed	 at	 analyzing	 whole	 genome	 datasets	 of	 patients	 originating	 from	
different	 countries	 across	 Europe	 and	 worldwide	 (ERDC	 consortium),	 initially	 screened	
and	 found	 to	 be	 negative	 following	 WES	 analysis.	 There	 are	 three	 main	 possible	
explanations	 for	 a	 WES	 investigation	 to	 mis	 disease-causative	 variants:	 i)	 insufficient	















Another	 explanation	 for	 “lost”	 candidate	 variants	 was	 pointed	 out	 by	 O’Rawe	 and	
colleagues81,	who	tested	five	different	mapping	and	variant	calling	pipelines	and	found	that	
only	about	57%	of	called	variants	were	concordant	(Figure	2).	On	the	other	hand,	0.5	to	5%	
of	 the	variants	were	unique	 to	 each	pipeline.	Altogether	 these	 findings	demonstrate	 that	
caution	 should	 be	 taken	 in	 interpreting	 negative	 findings,	 as	 variants	 might	 be	 missed	
depending	on	the	mapping	and	variant	calling	software	used,	as	well	as	false	positive	calls	
might	be	more	or	less	retained.	
Theoretically,	 if	 there	 are	 no	 mistakes	 due	 to	 mis-diagnosis	 or	 inaccuracy	 in	 DNA	
samples	handling,	 there	 is	one	 last	reason	 for	which	no	pathogenic	variant	 is	detected	 in	
any	WES	study:	the	variant	can	be	located	in	the	remaining	98%	of	the	patient’s	genome	as	
a	deep	intronic,	intergenic	or	structural	variation.	
An	 estimated	8%	of	 the	 general	 population	harbor	 in	 their	 genome	a	 large	 (>500	kb)	
deletion	or	duplication	with	at	an	allele	frequency	of	<	0.05%82.	There	is	growing	evidence	




















previously88.	 Genetic	 variants	 were	 identified	 using	 v2.0	 of	 the	 Complete	 Genomics	






We	 examined	 exomic	 and	 genomic	 data	 from	 a	 Spanish	 family	 composed	 of	 three	
siblings	with	 arRP.	Two	of	 them	were	 initially	 analyzed	by	WES	with	no	 genetic	 finding.	
What	 emerged	 from	 the	 subsequent	 WGS	 of	 one	 of	 the	 affected	 siblings	 is	 a	 56kb	







In	 addition,	 we	 found	 a	 rare	 non-synonymous	 heterozygous	 variant	 (p.Tyr2972Asp),	





CNGA1	 gene	 (chr4:	 47,931,964-47,946,798;	 hg19).	 The	 deletion	 of	 44.8	 kb	 fully	 removes	
five	exons.	Autozygome	analysis	revealed	several	regions	of	homozygosity,	CNGA1	lying	in	
one	of	them.	The	affected	mother’s	WES	data	were	re-assessed	and	was	indeed	found	to	be	
sufficiently	 covered	 in	 this	 region.	Although,	 supposedly,	 the	mother	 is	 carrier	of	at	 least	
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one	 healthy	 copy	 of	 the	 gene,	 she	 is	 affected	 with	 RP.	 By	 looking	 at	 the	 pedigree,	 and	
considering	the	consanguineous	relatedness	of	two	of	the	couples	of	this	family,	we	might	
consider	the	hypothesis	of	a	second	gene	involved	in	the	disease.	In	fact,	a	recent	study	on	a	









LCA	 case	 and	 found	 a	 large	 region	 of	 autozygosity	 (chr10:113’934-36’788’039).	 The	
parents	 were	 not	 declared	 as	 consanguineous.	 Deeper	 analysis	 of	 the	 SNP	 data	 in	 this	
region	 and	 flanking	 areas	 revealed	 that	 the	 patient	was	 carrying	 a	 duplicated	 portion	 of	
chr10	of	his	mother,	whereas	the	copy	of	the	father	was	missing.	In	this	autozygous	region	
we	 found	 a	 rare	non-synonymous	 variant	 in	 the	ACBD5	 gene	 (p.Val134Phe),	 affecting	 an	
evolutionarily	 conserved	 amino	 acid.	 This	 genomic	 region	 was	 not	 covered	 in	 the	WES.	
ACBD5	 was	 previously	 reported	 as	 a	 putative	 candidate	 for	 syndromic	 forms	 of	 retinal	






















Several	 cases	 were	 solved	 with	 the	 use	 of	 WGS,	 while	 WES	 was	 not	 efficient	 enough	
because	of	bad	coverage.	Table	1	and	Figure	6	show	an	overview	of	all	additional	findings	
in	the	examined	samples.	 In	total,	we	have	7	new	candidate	genes	for	novel	disease-gene	
associations	 that	 need	 further	 investigation	 for	 validation	 through	 segregation	 and	




















WGScode	 original_ID	 diagnosis	 finding	 variant_type	 category	
NEX1	 09/1325	 CSNB	 NYX	 nonsense	 known	gene	
NEX6	 09/1168	 arRP	+	hypoacusia	 DFNB31	 nonsense	 known	gene	
NEX8	 05/1117	 arRP	 EYS	 missense	+	deletion	 known	gene	
NEX9	 04/0654	 LCA	 ACBD5	 Missense	+	isodysomy	 known	gene	
NEX12	 3841	 arRP	 PDE6B	 splice	 known	gene	
NEX15	 737-2	 arUSH2A/RP	 ARSG	 missense	 NEW	GENE	
NEX17	 R220	 arRP	 CERKL	 misstart	 known	gene	
NEX18	 R69	 arRP	xl?	 NR2E3		 missense	+	splice	 known	gene	
NEX19	 R240	 arRP	 TNXB	 MEI	 NEW	GENE	
NEX20	 R240	 arRP	 CNGA3		 missense	 known	gene	
NEX28	 46200	 arRP	 no	candidates	 -	 unsolved	
NEX29	 46235	 arRP	 CACNA1S,	EDEM3	 missense	 NEW	GENE	
NEX30	 46238	 microphtal	 NDUFS3	 missense	 NEW	GENE	
NEX33	 48774	 arRP	 RP1L1/TUB	 missense	 known	gene	
NEX34	 58134	 WMS	 KCNQ5	 missense	 NEW	GENE	
NEX37	 58334	 arRP	 CNGA1	 deletion	 known	gene	













Today's	 questions	 in	 genomic	 research	 have	 reached	 a	 wide	 complexity,	 making	
traditional	 DNA	 sequencing	 technologies	 (i.e.	 Sanger	 sequencing)	 inefficient	 and	 time-
consuming.	 The	 NGS	 techniques,	 subject	 to	 constant	 improvements,	 have	 become	 an	
everyday	research	tool	to	address	these	questions.	
A	 bias	 exists	 in	 NGS	 analyses,	 since	 often	 the	 main	 focus	 of	 these	 investigations	
concentrates	 on	 the	 coding	 regions	 of	 the	 genome,	 corresponding	 to	 only	 2%	 of	 an	
individual’s	 genetic	makeup.	With	WGS	we	 can	 gain	 a	wider	 view	 and	 read	 every	 single	
base	of	the	remaining	98%	of	the	genome.	Although	there	is	still	need	for	development	of	
an	effective	pipeline	for	the	analysis	of	all	the	genetic	variations	in	a	full	genome,	WGS	can	
often	 ‘easily’	 detect	 large	 structural	 events.	 This	 was	 the	 case	 for	 three	 of	 our	 families,	
described	above.	
Nevertheless,	WGS	 helped	 finding	 the	 genetic	 causes	 of	 the	 disease	 in	 20	 of	 32	 cases	
(with	 known	 genes	 or	 candidate	 genes	 for	 novel	 disease-gene	 associations).	 From	 our	
results,	we	learned	that	quality	control	of	WES	data	needs	to	be	improved.	Principally,	we	
need	 to	develop	a	 systematic	and	automated	validation	of	 the	WES	coverage	 in	all	 genes	
already	known	 to	be	associated	with	 retinal	degeneration,	 a	 tool	 that	 is	being	developed	
presently	from	our	bioinformaticians,	and	that	will	be	integrated	in	our	pipeline.		
Even	 after	WGS,	 a	 number	 of	 cases	 remain	 unsolved.	Where	 is	 the	 causative	 variant?	
Possible	 answers	 might	 be	 in	 deep	 intronic	 or	 intergenic	 regions.	 To	 date,	 with	 the	
enormous	amount	of	data	collected	with	the	WGS,	it	is	nearly	impossible	for	us	to	verify	all	
the	 rare	 intronic	 variants	 that	 are	 called	 after	 WGS.	 An	 effective	 filtering	 pipeline	 for	
variants	 in	non-coding	 regions	 is	 nowadays	 extremely	needed	 in	 the	 community	 of	WGS	





reveal	 to	 be	 very	 expensive.	 On	 the	 other	 hand,	 for	 the	 study	 of	 recessive	 diseases,	
especially	 for	 cases	presenting	 consanguinity,	we	 can	exploit	 the	power	of	homozygosity	
mapping	to	considerably	reduce	the	number	of	candidate	variants.	
At	 the	 present-day,	 significant	 challenges	 in	NGS	 techniques	 persist;	 improvements	 in	






first	 line	 analysis	 tool	 to	 investigate	 the	 genetics	 of	 an	 inherited	 disease.	 Finally,	
technologic	improvement	is	allowing	structural	variant	detection	in	WES	data	as	well.	The	
research	community	is	constantly	producing	new	tools	for	NGS	data	analysis,	even	for	the	





Despite	 each	 project	 has	 been	 comprehensively	 discussed	 in	 its	 section,	 a	 few	
considerations	can	be	done	on	the	general	findings	composing	my	thesis.		
The	main	results	of	this	work	have	led	to	novel	disease-gene	associations,	in	particular	
for	 syndromic	 ciliopathies.	 In	 the	 year	 2000	 was	 published	 the	 first	 landmark	 paper	
responsible	 for	 considering	 cilia	 more	 than	 just	 vestigial	 elements.	 In	 this	 paper,	 the	
authors	 described	 the	 intraflagellar	 transport	 core	 component	 Ift88	 to	 be	 essential	 for	
primary	cilia	formation	in	Chlamydomonas	reinhardtii	and	in	mouse92.	This	study	provided	
the	 first	 evidence	 that	 intraflagellar	 transport	 was	 necessary	 for	 correct	 assembly	 and	
maintenance	of	 the	 ciliary	outer	 segment	 in	vertebrates.	 Since	 then,	 a	 cascade	of	 reports	
highlighted	the	importance	of	cilia	function	in	development	and	tissue	homeostasis.	Given	





primary	 cilium,	 leading	 for	 instance	 to	 defects	 in	 retina,	 renal	 function,	 hearing	 or	 bone	
development.	On	the	other	hand,	there	 is	a	different	category	of	ciliopathies	 that	have	no	
apparent	defects	in	the	primary	cilium,	whereas	motile	cilia	are	affected.	This	is	the	case	of	




with	 phenotypes	 in	 retina	 photoreceptors	 and	 spermatozoa,	 attest	 that	 some	 types	 of	
ciliopathies	 have	 an	 impact	 on	 both	 motile	 and	 immotile	 cilia.	 These	 results	 provide	
evidence	 of	 the	 existence	 of	 ciliary	 components,	 such	 as	 TTLL5	 and	 ARL2BP,	 that	 play	
crucial	 roles	 in	 both	 subtypes	 of	 cilia.	 Accordingly,	 although	 cilia	 and	 flagella	 have	 a	
different	morphology	and	functions,	they	may	share	a	similar	biochemistry.		
We	therefore	contributed	in	broadening	the	spectrum	of	ciliopathic	phenotypes,	presenting	
diseases	 that	 are	 in	 between	 immotile-	 or	 motile-only	 ciliopathies.	 Regarding	 TTLL5	
patients	specifically,	the	infertility	phenotype	was	not	fully	penetrant.	After	observation	of	
the	type	of	mutations	present	in	our	patient	cohort,	we	could	show	that	only	male	patients	
with	 truncating	 mutations	 had	 additional	 defects	 at	 the	 level	 of	 sperm.	 We	 therefore	
hypothesized	 an	 allele-specific	 effect,	 depending	 on	 the	 severity	 of	 the	 mutation	 at	 the	
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a	consequence	of	a	 faulty	ARL2BP,	however,	a	high	 incidence	of	 this	 laterality	defect	was	










In	 the	 fourth	 project,	 we	 performed	 a	 whole-genome	 sequencing	 investigation	 of	
unresolved,	 negative	 exomes,	 and	 we	 identified	 new	 structural	 variants	 in	 the	 EYS	 and	







in	 the	 NGS	 techniques,	 and	 the	 constant	 implementation	 of	 analytical	 pipelines.	We	 are	
often	biased	 in	NGS	analysis	because	 it	 is	more	 likely	to	 find	causative	variants	 in	coding	
regions.	 But	 there	 is	 growing	 interest	 in	 finding	methods	 for	 assessing	 pathogenicity	 of	
genetic	 variations	 in	 the	 noncoding	 portion	 of	 the	 genome.	 Other	 than	 more	 complex,	
multifactorial	 inheritance,	 we	 could	 suppose	 that	 the	 missing	 heritability	 could	 be	
explained	to	a	certain	extent	with	variants	in	noncoding	regions.		
As	 a	 researcher,	 living	 in	 this	 generation	 is,	 using	 simple	 words,	 a	 thrilling	 moment.	
















































































































































































































































































A homozygous founder missense variant in arylsulfatase G
abolishes its enzymatic activity causing atypical Usher
syndrome in humans
Samer Khateb, MD, PhD1, Björn Kowalewski, PhD2, Nicola Bedoni, MSc3, Markus Damme, PhD4,
Netta Pollack, BSc1, Ann Saada, PhD5, Alexey Obolensky, PhD1, Tamar Ben-Yosef, PhD6,
Menachem Gross, MD7, Thomas Dierks, PhD2, Eyal Banin, MD, PhD1, Carlo Rivolta, PhD3,8 and
Dror Sharon, PhD1
Purpose: We aimed to identify the cause of disease in patients
suffering from a distinctive, atypical form of Usher syndrome.
Methods: Whole-exome and genome sequencing were performed
in five patients from three families of Yemenite Jewish origin,
suffering from distinctive retinal degeneration phenotype and
sensorineural hearing loss. Functional analysis of the wild-type and
mutant proteins was performed in human fibrosarcoma cells.
Results: We identified a homozygous founder missense variant,
c.133G>T (p.D45Y) in arylsulfatase G (ARSG). All patients shared
a distinctive retinal phenotype with ring-shaped atrophy along the
arcades engirdling the fovea, resulting in ring scotoma. In addition,
patients developed moderate to severe sensorineural hearing loss.
Both vision and hearing loss appeared around the age of 40 years.
The identified variant affected a fully conserved amino acid that is
part of the catalytic site of the enzyme. Functional analysis of the
wild-type and mutant proteins showed no basal activity of p.D45Y.
Conclusion: Homozygosity for ARSG-p.D45Y in humans leads to
protein dysfunction, causing an atypical combination of late-onset
Usher syndrome. Although there is no evidence for generalized
clinical manifestations of lysosomal storage diseases in this set of
patients, we cannot rule out the possibility that mild and late-onset
symptoms may appear.
Genet Med advance online publication 4 January 2018
Key Words: arylsulfatase G; lysosomal storage disease; retinitis
pigmentosa; Usher syndrome; whole-exome sequencing
INTRODUCTION
Usher syndrome (USH) is the leading cause of inherited deaf-
blindness (MIM 268000). It is an autosomal recessive disease
with symptoms including visual disturbance due to retinal
degeneration and sensorineural hearing loss (SNHL) accom-
panied in some cases by vestibular areflexia. The prevalence of
USH has been estimated as 3.5–16.6 in 100,000 in several
populations.1–3 USH has historically been classified into three
subtypes according to the age of onset of the visual and
auditory symptoms, the severity of hearing loss, and the
presence of vestibular involvement: Usher type 1 (USH1) is
characterized by congenital SNHL with vestibular areflexia
and retinitis pigmentosa (RP) onset in the first decade of life;
USH2 by mild to moderate nonprogressive SNHL with RP
onset in the first or second decade of life and normal
vestibular function; and USH3 by progressive SNHL, some-
times accompanied by vestibular involvement, with a variable
time of onset of both SNHL and RP. However, cumulative
data have identified a large number of families with
phenotypes that are not compatible with any of the three
established types and are therefore considered as having
atypical forms of USH.4–6
USH is highly heterogeneous, not only clinically but also
genetically. Thirteen causative genes have been identified to
date, and three more loci are suspected to include additional
genes (RETNET database at https://sph.uth.edu/RetNet/). The
development of high-throughput sequencing techniques,
including whole-exome sequencing (WES) and whole-
genome sequencing (WGS), has contributed tremendously
to the identification of novel causative mutations and genes
for rare inherited diseases in general and retinal degeneration
in particular.7,8 Nevertheless, despite these advances, the
causative gene remains unknown in a large number of cases
with inherited retinal disease (IRD).9,10 Some of the proteins
encoded by USH-associated genes interact in complexes that
are localized to hair cells of the inner ear and in retinal
photoreceptors.11–13 USH-related proteins perform a variety
of cellular functions, including myosin-based motor transport
1Department of Ophthalmology, Hadassah–Hebrew University Medical Center, Jerusalem, Israel; 2Department of Chemistry, Biochemistry I, Bielefeld University, Bielefeld,
Germany; 3Department of Computational Biology, Unit of Medical Genetics, University of Lausanne, Lausanne, Switzerland; 4Department of Biochemistry, University of Kiel, Kiel,
Germany; 5Monique and Jacques Roboh Department of Genetic Research and the Department of Genetic and Metabolic Diseases, Hadassah-Hebrew University Medical Center,
Jerusalem, Israel; 6Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; 7Department of Otolaryngology—Head and Neck Surgery, Hadassah–
Hebrew University Medical Center, Jerusalem, Israel; 8Department of Genetics and Genome Biology, University of Leicester, Leicester, UK. Correspondence: Thomas Dierks or
Eyal Banin or Carlo Rivolta or Dror Sharon (thomas.dierks@uni-bielefeld.de or banine@cc.huji.ac.il or carlo.rivolta@unil.ch or dror.sharon1@gmail.com)
The last four authors contributed equally to this work.
Submitted 1 September 2017; accepted 6 November 2017; advance online publication 4 January 2018. doi:10.1038/gim.2017.227
GENETICS in MEDICINE | Volume 00 | Number | Month 1
© American College of Medical Genetics and Genomics ORIGINAL RESEARCH ARTICLE
	 103	
(MYO7A); cell–cell adhesion (CDH23 and PCDH15), scaffold
proteins (USH1C, ADGRV1, and SANS), and ciliary function
(ADGRV1 and C-Nap1).4,12,14 In the present study, we used a
combination of WES and WGS in a set of patients who share
the same ethnicity and the same distinctive phenotype in
order to identify the molecular cause of atypical USH.
MATERIALS AND METHODS
Patient recruitment
Three Yemenite Jewish families including five individuals
with USH (two patients in family MOL0120, two in family
MOL0737, and one in family TB55) were recruited for this
study. The tenets of the Declaration of Helsinki were followed,
the study was approved by the institutional review boards of
our respective institutions, and before donation of a blood
sample, written informed consent was obtained from every
individual who participated in this study.
Ocular examination
Ocular evaluation included a comprehensive ophthalmologic
exam, Goldmann perimetry, full-field electroretinography
(ffERG), electrooculography, color vision testing using the
Ishihara 38-panel and Farnsworth-Munsell D-15 tests and
color and pseudocolor fundus photos, optical coherence
tomography, and fundus autofluorescence (FAF) imaging.
Electrophysiological testing
International Society for Clinical Electrophysiology of Vision
standard ffERG was performed using monopolar corneal
electrodes (Henkes type; Medical Workshop, Groningen, The
Netherlands) and a computerized system (UTAS 3000; LKC,
Gaithersburg, MD). Cone responses to 30-Hz flashes of white
light were acquired under a background light of 21 cd/m2.
Scotopic responses, including a rod response to a dim blue
flash and a mixed cone–rod response to a standard white
flash, were acquired after 30–45 min of dark adaptation.
Between two and four sets of responses were recorded in each
condition for reproducibility. All ffERG responses were
filtered at 0.3 to 500 Hz, and signal averaging was applied.
Audiometry testing
Audiological screening included a comprehensive question-
naire (collecting information regarding any history of
exposure to noise, ototoxic agents, and genetic factors related
to hearing impairment), as well as physical and audiometric
examinations. An age-appropriate audiological examination
was performed, including pure-tone audiometry (250 Hz to
12,000 Hz), tympanometry, and transient-evoked otoacoustic
emission (TEOAE) for each ear. We used the following
scale to grade the degree of SNHL: slight, 16–25 dB hearing
loss; mild, 26–40 dB; moderate, 41–55 dB; moderately severe,
56–70 dB; severe, 71–90 dB, and profound, over 90 dB.
Specific types of SNHL were determined by audiometric
curve patterns: ascending (hearing loss greater at the
lower frequencies), flat, descending (hearing loss greater
at the higher frequencies), and U-shaped (hearing loss at
mid-frequencies) curves. Otoacoustic emissions have been
suggested as a sensitive measure of cochlear function with the
potential for preclinical detection of damage. TEOAE tests
were conducted on the same day as the pure tone test. A
response at three frequencies of 3 dB or greater above the
background with a minimum of 70% reproducibility at each
frequency and 90% or greater stability was required for
passing the TEOAE test. TEOAE examination was categorized
as either pass or fail for each ear.
Genetic analyses
Homozygosity mapping was performed using whole-genome
single-nucleotide polymorphism microarrays (Affymetrix 6.0,
USA and Illumina, San Diego, CA) and analyzed using
HomozygosityMapper (http://www.homozygositymapper.
org). WES analysis of individuals MOL0120 III:2 and
MOL0737 II:2 was performed at Otogenetics (Norcross,
GA) using Agilent V4 (Santa Clara, CA, USA) and Illumina
HiSeq 2000 with 30× coverage. WES analysis of individual
TB55 II:1 was performed at the Technion Genome Center,
using the Nextera Expanded Exome Enrichment Kit (Illu-
mina, USA) and Illumina HiSeq2500 at 30× coverage.
Sequence reads were aligned to the human genome reference
sequence (hg38), and variant filtering analysis was performed.
WGS
WGS was performed using the Complete Genomics platform
(format version 2.5), and the data were analyzed as described
previously.9
Primer design
Primers for mutation screening were designed using the
Primer3 software and Sanger sequencing of polymerase chain
reaction (PCR) products was used to verify the mutation and
to screen additional patients and controls.
Reverse-transcriptase PCR
Retinal RNA was isolated from human retinas using TRI
Reagent (Sigma-Aldrich, St Louis, MO), and RNA derived
from different human tissues was purchased (Clontech,
Mountain View, CA, USA; cat. 636643, lot 8101369A).
Complementary DNA was synthesized using the Verso cDNA
kit (Thermo Fisher Scientific, Waltham, MA, USA) in
accordance with the manufacturer’s protocol. The PCR-
specific primers for arylsulfatase G (ARSG) and an internal
control (PGM1) are listed in Supplementary Table S3 online.
Lysosomal enzymatic activities
The lysosomal activities in plasma and leukocytes were
determined using standard fluorimetric methods (as described
by Z. Lukacs in Laboratory Guide to the Methods in
Biochemical Genetics (N. Blau, M. Duran, and K.M. Gibson,
eds), Springer: Berlin, Germany, 2008:287–324).
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Mutagenesis and cloning
The ARSG-D45Y mutant was generated by site-directed
mutagenesis using a pCI-neo hARSG-WT construct as
template encoding human wild-type ARSG equipped with a
C-terminal RGS-His6 tag.15 PCR was conducted using Kapa
HiFi polymerase (Kapa Biosystems, Wilmington, MA, USA)
and the primers 5′-gtgattattttggccgattacatggggtggggtg-3′ and
5′-caccccaccccatgtaatcggccaaaataatcac-3′, respectively. All
plasmids were controlled by Sanger sequencing of the ARSG
insert.
Generation and cultivation of stable cell lines
HT1080 fibrosarcoma cells were transfected with the pCI-neo
hARSG-D45Y plasmid using PEI (Polysciences Europe
GmbH, Hirschberg an der Bergstrasse, Germany) in Opti-
MEM (Gibco, Thermo Fisher Scientific, Waltham, MA,
USA). Stably transfected cell clones were selected by adding
800 μg/ml Geniticin (G-418) for 14 days of culture. Clones
were screened for ARSG expression by immunoblotting using
anti-RGS-His6 (Qiagen, Hilden, Germany), anti-ARSG (R&D
Systems, Minneapolis, MN, USA) and anti-GAPDH Santa
Cruz, Santa Cruz, Dallas, TX, USA; Invitrogen, Carlsbad, CA,
USA) antibodies together with corresponding HRP-coupled
secondary antibodies (Invitrogen, Carlsbad, CA, and Dianova,
Hamburg, Germany). The cell lines expressing ARSG wild
type and the ARSG-C84A mutant had been generated in a
previous study.15 Cells were grown in Dulbecco’s Modified
Eagle Medium (Invitrogen) containing 10% FCS (PAN),
2 mM glutamine (Lonza, Basel, Switzerland), and penicillin/
streptomycin (Lonza, Basel, Switzerland) under standard
culture conditions (37 °C, 5% CO2).
Sulfatase activity quantification
Cell lysates were prepared in ice-cold lysis buffer (TBS with
1 mM PMSF, 5 mM IAA, 1 mM EDTA and 0.1% (v/v) Triton
X-100). For this purpose, cell pellets were resolved in lysis
buffer and sonified (3 × 20 s, 40% intensity, 4 °C, Branson
Sonifier, Slough, UK). The lysates were cleared by centrifuga-
tion at 18,000g at 4 °C for 15 min, and protein concentration
was determined using the DC Protein Assay (Bio-Rad,
Hercules, CA) with bovine serum albumen as a standard.
Sulfatase activity was measured using the pseudosubstrate
paranitrocatechol sulfate (Sigma-Aldrich Chemie Gmbh,
Munich, Germany) as described previously.16 Specific activ-
ities were calculated and normalized according to western blot
signals, i.e., after ARSG quantification by SDS-PAGE and
immunoblotting using polyvinylidene fluoride membranes
and the antibodies listed above. Band intensities were
determined using ImageJ. Statistical analyses were conducted
with GraphPad Prism (GraphPad Software, La Jolla, CA).
Molecular modeling and structural analysis
The ARSG structure was modeled using SwissModel with the
structures of human arylsulfatase A (ARSA) (PDB 1e1z) or a
catalytic formylglycine (FGly)-ester of human ARSA (PDB
1n2k) as templates. The ARSG and ARSA structures were
visualized and manipulated using PyMol (DeLano Scientific,
Palo Alto, CA).
RESULTS
Clinical description of recruited patients
In our cohort of more than 1,500 Israeli and Palestinian
families with IRDs, five affected individuals from three
families shared the same ethnicity (Yemenite Jewish) and
presented with a particular combination of late-onset IRD and
SNHL. While some variability was present in the clinical
manifestations among subjects (detailed case reports are
provided in Supplementary Information Appendix), a
characteristic pattern could be identified: all affected
individuals presented with a distinctive retinal phenotype,
including ring-shaped retinal atrophy delimiting the vascular
arcades temporally and extending beyond the optic nerve
nasally, with relative preservation of the mid- and far-
periphery. Over time, pigment migration occurred within the
atrophic areas, forming bone spicule–like pigmentary changes
as well as pigment clumps, and the central macula also
became involved (Figure 1). Fundus autofluorescence
imaging using the Optos ultrawide-field retinal camera
emphasized the areas of involvement, showing the hypo-
fluorescent ring of atrophy surrounded by hyperfluorescent
borders (Figure 1). On vertical and horizontal optical
coherence tomography imaging, retinal thinning with loss of
the outer retinal layers was evident also within the macular
area, including the fovea at later ages (Figure 1). Functionally,
Goldmann visual fields correlated with the structural changes,
showing a central ring scotoma with relative preservation of
central vision at earlier stages of disease. Later on, this
progressed to involve the macular area with development of
central scotomas, while mid- and far-peripheral visual fields
remained relatively preserved (Supplementary Figure S1).
Electroretinographic testing showed severely decreased rod
and mixed cone–rod responses (Table 1). Electrooculography
testing was performed in three affected individuals and the
Arden ratio was found to be reduced (Table 1). These
findings suggest injury to the retinal-pigmented epithelium,
either as a primary event or secondary to photoreceptor
degeneration. With regard to involvement of the auditory
system, all affected subjects presented with progressive
moderate to severe SNHL at a relatively late age (usually
after the age of 40 years—Supplementary Figure S2 online
and Supplementary Table S1). None of the affected
individuals reported significant abnormalities of the
vestibular system (detailed description in Supplementary
Information). In addition, the following clinical evaluations
and tests performed in the affected individuals were all within
normal limits: lack of neurological abnormalities (all affected
individuals), normal brain magnetic resonance imaging
(performed on one patient), normal abdominal ultrasound
exam (performed in two of the patients), and normal
biochemical blood and urine tests (four patients).
Osteoporosis, as determined by bone density measurements,
is present in one of the patients and osteopenia in the two
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sisters of family MOL0737. It should be noted that at the time
of all the above testing the patients were of middle age or
beyond, between the ages of 50 and 72.
Genetic analysis of study participants
Aiming to identify the cause of disease in these families, we
initially performed homozygosity mapping on four indivi-
duals (MOL0737 II:1, MOL0737 II:2, MOL0120 III:1, and
TB55 II:1—Figure 2a), using single-nucleotide polymorphism
arrays. Following analysis with HomozygosityMapper, family
MOL0737 revealed two large homozygous regions (a 9.3 Mb
region on chr. 5: 126.2–135.5 Mb and a 4-Mb region on chr.
17: 66–70Mb), shared by the two affected sisters, neither of
which included a known USH gene or a clear-cut candidate
for the disease. Homozygosity mapping of MOL0120 III:1
revealed four large homozygous regions (more than 20Mb),
one of which on chr. 17 (50.4–76.4 Mb) showed overlap with
the one identified in family MOL0737. Patient TB55 II:1
harbored eight homozygous regions of over 10 Mb each, one
of which was a 12.58-Mb homozygous region on chr. 17
(56.8–69.4 Mb). All four patients had a 3.4-Mb identical
haplotype on chr. 17 (66–69.4 Mb). We subsequently
performed WES analysis on three samples (MOL0737 II:2,
MOL0120 III:1, and TB55 II:1, Figure 2a) and WGS on one
sample (MOL0737 II:1), and all were negative for suspected
disease-causing mutations in any of the 226 known IRD
genes.17 WES and WGS data were also analyzed for
homozygosity and the combined information revealed a
single shared homozygous region on chr. 17 (66–69.4 Mb).
Variant analysis revealed a single shared missense transver-
sion, c.133G>T, p.D45Y (chr.17: 66303768G>T), in exon 2
of ARSG (NM_014960.4), which was validated by Sanger
sequencing (Supplementary Figure S3) and found to be in a
homozygous state in all five affected individuals. All
haplotypes surrounding the variant site were identical and
this variant is therefore a founder mutation.
To rule out the possibility that the ARSG c.133G>T variant
is a polymorphism in the Yemenite Jewish population, we
screened 101 controls and identified one heterozygous
individual (this corresponding to a minor allele frequency of
0.005). In addition, the variant does not appear in any of the
available databases, including gnomAD (with 246,228
sequenced alleles of various origins). We subsequently used
Sanger sequencing of exon 2 to screen the remaining unsolved
IRD index cases of Yemenite origin (n = 19) for p.D45Y, as
well as other mutations in this exon. The analysis revealed
Figure 1 Retinal imaging of patients homozygous for the p.D45Y ARSG mutation. (a–g) MOL0737 II:1 (56 years), (h–n) MOL0737 II:2 (55
years), (o and p) MOL0120 III:2 (72 years), (q–v) MOL0120 III:1 (69 years). a, h, o, s and b, i, p, t represent ultrawide-field pseudocolor and FAF photos,
respectively, taken using the Optos Panoramic 200 Optomap Fundus Camera. Characteristic ring-shaped atrophic changes accompanied by intraretinal
pigment migration along the major vascular arcades and extending beyond the optic disc can be seen. (e and l) Goldmann visual field of the parallel
fundus photos (a and h), respectively, each showing the corresponding ring-shaped scotoma. (c, d, j, and k) Heidelberg Spectralis multicolor fundus
photos and FAF of the posterior pole of subjects MOL0737 II:1 and MOL0737 II:2, respectively. (q and r) Spectralis FAF images of the posterior pole of
subject MOL0120 III:1, demonstrating macular involvement. (f, g, m, n, u, and v) are optical coherence tomography sections showing retinal thinning
and loss of the outer retinal layers in the macular area of subjects MOL0737 II:1, MOL0737 II:2 and MOL0120 III:1, respectively.





Refraction Full field ERG results EOG (%)
Cone flicker—






(55) ND ND 25, 37.2 a-18, b-40 20 100
(62) ND − 2.68 ND ND ND ND
(65) 0.2 ND ND ND ND ND
MOL0120 III:2
(75) 0.0001 NA NA NA NA NA
MOL0737 II:1
(58) 0.3 +5.18 56, 34 a-85, b-129 98 133
MOL0737 II:2
(47) 0.8 +1.50 63, 31 a-118, b-341 227 146
(55) 0.7 +2.50 84, 32 a-104, b-209 141 143
TB55 II:1
(51) NA NA 24, 35 a-52, b-70 45 NA
EOG, electroretinography; IT, implicit time; NA, not available; ND, not done.
Best corrected visual acuity is presented in decimal values as an average of the two eyes.
Cone Flicker 30 Hz—lower normal threshold: amplitude—60 μV; response interval—33 msec; mixed cone–rod response—normal lower threshold of b wave: 400 μV;
blue-light rod response—lower normal threshold: 200 μV; EOG—normal average 250%, lower threshold—185%.
aAge at testing is indicated in parentheses.
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a single heterozygous case with early-onset RP and normal
hearing at the age of 46 years. Sequencing analysis of all ARSG
exons failed to detect a second possible pathogenic variant in
this individual, and we therefore predict that she carries p.
D45Y by chance, while the disease-causing mutation lies in a
yet-to-be-identified RP-causing gene. The genotype difference
between the cohort of IRD families (three homozygous: one
heterozygous: 18 wt) and controls (none homozygous: one
heterozygous: 100 wt) of Yemenite Jewish origin is statistically
significant (po 4.0 × 10− 4). Aiming to expand the ARSG
tissue expression profile,18 we performed reverse-transcriptase
PCR analysis of 17 different human tissues, which revealed
a ubiquitous pattern, with ARSG being expressed in
the majority of the studied tissues, including the retina
(Supplementary Figure S4).
p.D45 is critical for ARSG function
In the encoded arylsulfatase G (ARSG) enzyme, an ensemble
of ten conserved amino acid residues forms the catalytic
pocket, as holds true for type I sulfatases in general.18,19 For
ARSG, one of these ten residues is aspartate at position 45.
This amino acid is therefore extremely important and did not
tolerate any substitution in the course of evolution (Figure
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Figure 2 ARSG mutation impact on the ARSG active site structure. (a) Pedigrees of families with the ARSG mutation. Filled symbols designate
affected individuals. Red arrows represent index cases. Family number is depicted above each family tree and individual number below each symbol.
The ARSG genotype of recruited individuals is depicted below the individual number: M, c.133G> T. Applied sequencing techniques are presented as
acronyms above each subject. (b) Multiple alignment of the amino acid sequence flanking the ARSG-p.D45 mutated amino acid shows complete
preservation of the aspartate in different species. (c) Multiple alignment of the amino acid sequence flanking the mutated amino acid shows
preservation of the relevant aspartate in 16 of the 17 human members of the sulfatase family. (d) A WebLogo image showing the relative preservation
of amino acids around ARSG-p.D45 in 74 related sequences. (e) Modeling of the human ARSG active site. The structure of human ARSG was modeled
using human arylsulfatase A (ARSA), the closest homologue of ARSG, as a template (PDB code 1e1z). The model is presented as surface structure. The
green color indicates the catalytic Cα-formylglycine (FGly) residue, which is located next to a cavity in the ARSG surface. Mutation of aspartate-45
(magenta) to tyrosine (red) positions the phenolic ring of the tyrosine within this cavity, thereby altering the accessibility of the FGly and interfering with
substrate desulfation. (f) Molecular structure of the calcium-binding site of ARSA. (Left) The four complexing aspartate and asparagine residues are
shown in white with heteroatoms shown in red and blue. The FGly residue is shown in green. The complexed metal ion is represented by the green
sphere. In this structure (PDB code 1n2k) a critical intermediate of the catalytic cycle was trapped using 4-methylumbeliferyl phosphate as a substrate
surrogate which leads to FGly phosphorylation, thereby mimicking the physiological FGly sulfation. The phosphor atom is shown in orange. (Right)
Upon D30Y mutation the tyrosine side chain clashes with the phosphate group, indicating sterical hindrance of substrate binding and, consequently, of
covalent FGly-ester formation. In addition, the coordination of the metal ion will be massively distorted.
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ARSG orthologues (Figure 2d, which is based on 74 ARSG-
related sequences) but also among 16 of the 17 members of
the human sulfatase family (Figure 2c). Of note, mutations in
the corresponding aspartate residue in N-sulfoglucosamine
sulfohydrolase (encoded by SGSH) and N-
acetylgalactosamine-6-sulfatase (encoded by GALNS) cause
loss-of-function alleles resulting in different forms of
mucopolysaccharidosis (MPS type IIIA and IVA, respec-
tively).20,21
Arylsulfatase G was identified in 2002 as a novel sulfatase
gene18 and has been further characterized biochemically as a
lysosomal sulfatase.15 As mentioned above, aspartate-45 is
part of the ARSG active site, where it coordinates a calcium
ion next to the catalytic formylglycine (FGly) residue that is
essential for all human sulfatases.22 Figure 2e shows the
surface structure of the ARSG active site, as modeled on the
known structure of human ARSA, i.e., the closest relative of
ARSG (see Figure 2c). A tyrosine (Figure 2e, red) replacing
the aspartate (magenta), as found in the patients described
here, fills part of the active site cavity next to the FGly (green).
The bulky tyrosine side-chain leaves no space for formation of
the FGly-sulfate ester, which is an essential intermediate of
the catalytic cycle,23 as shown in Figure 2f on the basis of a
published crystal structure with a trapped ester intermediate
in ARSA.24 In addition, a loss of the calcium ion may be
predicted as a consequence of a massively distorted
coordination, because the tyrosine hydroxyl at a distance of
4.0 Å is too remote (2.4 Å for the wild-type aspartate carboxyl
group). Loss of the calcium ion in turn may also affect protein
stability.
ARSG-p.D45Y abolishes enzyme activity but does not lead
to significant glycosaminoglycan excretion in patients
To test these predictions experimentally, ARSG was stably
expressed in human fibrosarcoma HT1080 cells, one of the
most efficient cell lines used for production of human
sulfatases.15,25 Three independent clones expressing the p.
D45Y-mutant were compared to wild-type ARSG, as well as
to the null-mutant ARSG-p.C84A (Figure 3), which lacks the
catalytic FGly-84 (deriving from the posttranslational mod-
ification of Cys84).26 No significant sulfatase activity was
detectable in the p.D45Y clones (Figure 3a, b), despite the
fact that all ARSG variants were expressed at similar levels
(Figure 3c). The measured residual activity (o20% of ARSG
wild type) was in fact as low as that observed for the p.C84A
null mutant (Figure 3a,b) and can be attributed to the
endogenous sulfatase activity present in the HT1080 cells.15 In
addition to this marked impairment of enzymatic activity of
ARSG-p.D45Y, we observed lack of processing of the ARSG
precursor protein (63 kDa) into its mature three chains, of
which the largest subunit (~30 kDa in humans),16 could be
detected only for the wild-type protein (Figure 3d). Lack of
processing was observed earlier also for ARSG-p.C84A
(unpublished data) and also for active site mutants of two
other human sulfatases.27,28 While this maturation of ARSG is
dispensable for enzymatic activity in vitro, the observed lack
of in vivo processing, which relies on the lysosomal proteases
cathepsin B and L,16 suggests that ARSG-p.D45Y is
improperly transported to the lysosomes. To conclude, the
p.D45Y-mutation, apart from blocking the catalytic activity,
clearly affects maturation and probably also trafficking of the
enzyme to its target organelle. However, a drastic decrease in
stability of the ARSG-p.D45Y precursor protein was not
observed (Figure 3c,d).
Since the ARSG-KO in the mouse model and also
mutations in genes that are paralogous to ARSG cause
phenotypes affecting additional lysosomal enzymes and
catabolic pathways,29,30 we tested patient samples for
biochemical parameters that might be affected by ARSG
deficiency (Supplementary Table S2). However, the
enzymatic activities of β-galactosidase, total hexosaminidase,
and arylsulfatase A in plasma samples of two patients, as well
as α-L-iduronidase and β-galactosidase in leukocytes, were all
within normal ranges. Of note, urinary glycosaminoglycans
were at the upper limit of the normal range (Supplementary
Table S2).
DISCUSSION
We report here that a mutation in a gene encoding a
lysosomal protein, ARSG, causes atypical USH in humans.
Patients homozygous for the p.D45Y variant manifest a late-
onset rod-cone dystrophy with development of atrophy and
pigmentary changes encroaching the posterior pole and
causing a ring scotoma, which later progresses to involve
the macula and fovea while the mid- and far-periphery of the
retina are relatively preserved. This is accompanied by
progressive moderate to severe SNHL.
In other species, mutated canine ARSG on the basis of its
symptomatic presentation has been reported to cause late-
onset neuronal ceroid lipofuscinosis (NCL),31 a neurodegen-
erative lysosomal storage syndrome that includes static and
dynamic ataxia and cerebellar atrophy. Although NCL in
other models usually also triggers retinal degeneration (but
not hearing loss), none of the 138 studied dogs showed visual
impairment. In mice, Arsg knockout showed that the protein
in fact is responsible for the degradation of 3-O-sulfated N-
sulfoglucosamine residues of heparan sulfate glycosaminogly-
cans, causing a new form of lysosomal storage disease, which
was termed MPS IIIE.32,33 These mice were shown to also
have photoreceptor degeneration.34 In this context, it should
be mentioned that retinal degeneration is a very common
finding in many human lysosomal storage diseases, including
NCL and MPS. Remarkably, photoreceptor degeneration in
Arsg-knockout mice appeared clearly before manifestation of
symptoms affecting the central nervous system, including
Purkinje cell loss and ataxia. The USH patients described here
did not show any neurological symptoms or signs of
peripheral lysosomal storage, even at a relatively old age
(the oldest patient described here is 72 years old), but we
cannot rule out the possibility that mild and very late-onset
symptoms may appear. The phenotype in humans indicates
that, as in mice, the retina is among the primary tissues
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affected by ARSG deficiency, suggesting that 3-O-sulfated
heparan sulfate has an important physiological function in the
retina and the inner ear. Nevertheless, it should also be
mentioned that in both NCL (type CLN7) and MPS (type
IIIC), diseases that are generally fatal in late adolescence or
early adulthood,35,36 an increasing number of patients were
recently described as expressing isolated RP, while the severe
neurological and peripheral somatic features that are typically
observed in both diseases were lacking.37–39 In this respect, it
should also be noted that the (almost) normal level of urinary
glycosaminoglycans in our patients is not in accordance with
findings among classical MPSs. Thus, ARSG patients are
likely to be missed in the first-line screening for MPS diseases.
Interestingly, also other MPS III cases were occasionally
reported who presented with urinary glycosaminoglycan
levels in the normal range.40
The phenotype which we describe here differs from the
three accepted USH types that were defined historically, and
adds to the large number of “atypical” USH cases that has
emerged in recent years. This may further emphasize the need
to update the nomenclature of USH syndrome, in order to
better distinguish between the different USH subtypes.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the
paper at http://www.nature.com/gim
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Figure 3 Functional analysis of the ARSG-p.D45Y variant. (a and b) Cell lysates of HT1080 cells, stably overexpressing ARSG wild type, the null-
mutant C84A, or the D45Y mutant (independent cell clones D45Y a, D45Y b and D45Y c), were subjected to sulfatase activity assays using the
chromogenic pseudosubstrate para-nitrocatechol sulfate. The enzyme reaction was terminated after 60 min (a) or after 30, 60, and 240 min (b), as
indicated. The given specific activities were normalized according to western blot signals, using an anti-RGS-His6 antibody (c) to correct for differences in
mutant expression. These corrections explain the apparently lower activity for the high-expressing D45Y clones a and b, as compared to D45Y clone c and
the C84A null-mutant, all of which in fact show only background activities owing to endogenous sulfatases. Error bars represent standard deviation from
three experiments. (d) Analysis of ARSG processing. Cell lysates of overexpressing cells were blotted and ARSG was detected using an anti-ARSG antibody.
The processed ~30 kDa form of mature ARSG was observed only for ARSG-WT. GAPDH detection served as loading control (c and d).
ORIGINAL RESEARCH ARTICLE KHATEB et al | Arylsulfatase G dysfunction causes Usher syndrome




The authors declare no conflict of interest
REFERENCES
1. Boughman JA, Vernon M, Shaver KA. Usher syndrome: definition and
estimate of prevalence from two high-risk populations. J Chronic Dis.
1983;36:595–603.
2. Rosenberg T, Haim M, Hauch AM, Parving A. The prevalence of Usher
syndrome and other retinal dystrophy-hearing impairment associations.
Clin Genet. 1997;51:314–321.
3. Kimberling WJ, Hildebrand MS, Shearer AE, et al. Frequency of Usher
syndrome in two pediatric populations: implications for genetic
screening of deaf and hard of hearing children. Genet Med. 2010;12:
512–516.
4. Khateb S, Zelinger L, Mizrahi-Meissonnier L, et al. A homozygous
nonsense CEP250 mutation combined with a heterozygous nonsense
C2orf71 mutation is associated with atypical Usher syndrome. J Med
Genet. 2014;51:460–469.
5. Bashir R, Fatima A, Naz S. A frameshift mutation in SANS results in
atypical Usher syndrome. Clin Genet. 2010;78:601–603.
6. Liu XZ, Hope C, Walsh J, et al. Mutations in the myosin VIIA gene cause a
wide phenotypic spectrum, including atypical Usher syndrome. Am J Hum
Genet. 1998;63:909–912.
7. Pierrache LHM, Kimchi A, Ratnapriya R, et al. Whole-exome sequencing
identifies biallelic IDH3A variants as a cause of retinitis pigmentosa
accompanied by pseudocoloboma. Ophthalmology 2017;124:992–1003.
8. Gong B, Wei B, Huang L, et al. Exome sequencing identified a recessive
RDH12 mutation in a family with severe early-onset retinitis pigmentosa. J
Ophthalmol. 2015;2015:942740.
9. Nishiguchi KM, Tearle RG, Liu YP, et al. Whole genome sequencing in
patients with retinitis pigmentosa reveals pathogenic DNA structural
changes and NEK2 as a new disease gene. Proc Natl Acad Sci USA.
2013;110:16139–16144.
10. Carss KJ, Arno G, Erwood M, et al. Comprehensive rare variant analysis
via whole-genome sequencing to determine the molecular pathology of
inherited retinal disease. Am J Hum Genet. 2017;100:75–90.
11. Kremer H, van Wijk E, Marker T, Wolfrum U, Roepman R. Usher
syndrome: molecular links of pathogenesis, proteins and pathways. Hum
Mol Genet. 2006;15 Spec No 2:R262–270.
12. Reiners J, Nagel-Wolfrum K, Jurgens K, Marker T, Wolfrum U. Molecular
basis of human Usher syndrome: deciphering the meshes of the Usher
protein network provides insights into the pathomechanisms of the Usher
disease. Exp Eye Res. 2006;8397–119.
13. El-Amraoui A, Petit C. The retinal phenotype of Usher syndrome:
pathophysiological insights from animal models. C R Biol. 2014;337:
167–177.
14. Flanagan AM, Stavenschi E, Basavaraju S, Gaboriau D, Hoey DA,
Morrison CG. Centriole splitting caused by loss of the centrosomal
linker protein C-NAP1 reduces centriolar satellite density and impedes
centrosome amplification. Mol Biol Cell. 2017;28:736–745.
15. Frese MA, Schulz S, Dierks T. Arylsulfatase G, a novel lysosomal sulfatase.
J Biol Chem. 2008;283:11388–11395.
16. Kowalewski B, Lubke T, Kollmann K, et al. Molecular characterization of
arylsulfatase G: expression, processing, glycosylation, transport, and
activity. J Biol Chem. 2014;289:27992–28005.
17. Beryozkin A, Shevah E, Kimchi A, et al. Whole exome sequencing reveals
mutations in known retinal disease genes in 33 out of 68 Israeli families
with inherited retinopathies. Sci Rep. 2015;5:13187.
18. Ferrante P, Messali S, Meroni G, Ballabio A. Molecular and biochemical
characterisation of a novel sulphatase gene: arylsulfatase G (ARSG). Eur J
Hum Genet. 2002;10:813–818.
19. Waldow A, Schmidt B, Dierks T, von Bulow R, von Figura K. Amino acid
residues forming the active site of arylsulfatase A. Role in catalytic activity
and substrate binding. J Biol Chem. 1999;274:12284–12288.
20. Beesley CE, Young EP, Vellodi A, Winchester BG. Mutational analysis of
Sanfilippo syndrome type A (MPS IIIA): identification of 13 novel mutations.
J Med Genet. 2000;37:704–707.
21. Morrone A, Tylee KL, Al-Sayed M, et al. Molecular testing of 163 patients
with Morquio A (mucopolysaccharidosis IVA) identifies 39 novel GALNS
mutations. Mol Genet Metab. 2014;112:160–170.
22. Schmidt B, Selmer T, Ingendoh A, von Figura K. A novel amino acid
modification in sulfatases that is defective in multiple sulfatase deficiency.
Cell 1995;82:271–278.
23. Boltes I, Czapinska H, Kahnert A, et al. 1.3 A structure of arylsulfatase from
Pseudomonas aeruginosa establishes the catalytic mechanism of sulfate ester
cleavage in the sulfatase family. Structure 2001;9:483–491.
24. Chruszcz M, Laidler P, Monkiewicz M, Ortlund E, Lebioda L, Lewinski K.
Crystal structure of a covalent intermediate of endogenous human
arylsulfatase A. J Inorg Biochem. 2003;96:386–392.
25. Dierks T, Schmidt B, Borissenko LV, et al. Multiple sulfatase deficiency is
caused by mutations in the gene encoding the human C(alpha)-formylglycine
generating enzyme. Cell 2003;113:435–444.
26. Dierks T, Lecca MR, Schlotterhose P, Schmidt B, von Figura K. Sequence
determinants directing conversion of cysteine to formylglycine in
eukaryotic sulfatases. EMBO J. 1999;18:2084–2091.
27. Daniele A, Di Natale P. Heparan N-sulfatase: cysteine 70 plays a role in
the enzyme catalysis and processing. FEBS Lett. 2001;505:445–448.
28. Millat G, Froissart R, Maire I, Bozon D. Characterization of iduronate
sulphatase mutants affecting N-glycosylation sites and the cysteine-84
residue. Biochem J. 1997;326 (Pt 1):243–247.
29. Van Hoof F, Hers HG. The abnormalities of lysosomal enzymes in
mucopolysaccharidoses. Eur J Biochem. 1968;7:34–44.
30. Vitner EB, Platt FM, Futerman AH. Common and uncommon pathogenic
cascades in lysosomal storage diseases. J Biol Chem. 2010;285:
20423–20427.
31. Abitbol M, Thibaud JL, Olby NJ, et al. A canine arylsulfatase G (ARSG)
mutation leading to a sulfatase deficiency is associated with neuronal ceroid
lipofuscinosis. Proc Natl Acad Sci USA. 2010;107:14775–14780.
32. Kowalewski B, Heimann P, Ortkras T, et al. Ataxia is the major
neuropathological finding in arylsulfatase G-deficient mice: similarities
and dissimilarities to Sanfilippo disease (mucopolysaccharidosis type III).
Hum Mol Genet. 2015;24:1856–1868.
33. Kowalewski B, Lamanna WC, Lawrence R, et al. Arylsulfatase G inactivation
causes loss of heparan sulfate 3-O-sulfatase activity and mucopolysacchar-
idosis in mice. Proc Natl Acad Sci USA. 2012;109:10310–10315.
34. Kruszewski K, Lullmann-Rauch R, Dierks T, Bartsch U, Damme M.
Degeneration of photoreceptor cells in arylsulfatase G-deficient mice.
Invest Ophthalmol Vis Sci. 2016;57:1120–1131.
35. Kousi M, Siintola E, Dvorakova L, et al. Mutations in CLN7/MFSD8 are a
common cause of variant late-infantile neuronal ceroid lipofuscinosis.
Brain 2009;132(Pt 3):810–819.
36. Wraith JE. Mucopolysaccharidoses and oligosaccharidoses. In: Fernandes
J, Saudubray JM, van den Berghe G, Walter JH, (eds). Inborn Metabolic
Diseases. Diagnosis and Treatment. Vol 4. Springer: Heidelberg, Germany,
2006:496–507.
37. Khan KN, El-Asrag ME, Ku CA, et al. Specific alleles of CLN7/MFSD8, a
protein that localizes to photoreceptor synaptic terminals, cause a
spectrum of nonsyndromic retinal dystrophy. Invest Ophthalmol Vis Sci.
2017;58:2906–2914.
38. Roosing S, van den Born LI, Sangermano R, et al. Mutations in MFSD8,
encoding a lysosomal membrane protein, are associated with
nonsyndromic autosomal recessive macular dystrophy. Ophthalmology
2015;122:170–179.
39. Haer-Wigman L, Newman H, Leibu R, et al. Non-syndromic retinitis
pigmentosa due to mutations in the mucopolysaccharidosis type IIIC
gene, heparan-alpha-glucosaminide N-acetyltransferase (HGSNAT). Hum
Mol Genet. 2015;24:3742–3751.
40. Giugliani R. The mucopolysaccharidoses. In: Metha A, Winchester, B.,
(eds). Lysosomal Storage Disorders: A Practical Guide: John Wiley:
Chichester, UK, 2012:94–100.
Arylsulfatase G dysfunction causes Usher syndrome | KHATEB et al ORIGINAL RESEARCH ARTICLE

































fibroblasts	starting	 from	skin	biopsies	of	 two	patients.	 In	addition	 I	made	Figure	2,	using	
the	 raw	 data	 of	 the	 pure	 tone	 audiometry	 from	 patients	 and	 from	 publicly	 available	
measurements.		
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